Unnamed: 0,file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT82,[1],"Schweizer J, Bowden PE, Coulombe PA, et al. 2006. J Cell Biol. New consensus nomenclature for mammalian keratins.",10.1083/jcb.200603161,https://doi.org/10.1083/jcb.200603161,New consensus nomenclature for mammalian keratins,Schweizer
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT82,[2],"Coulombe PA, Omary MB. 2002. Nat Rev Mol Cell Biol. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments.",10.1016/s0955-0674(01)00301-5,https://doi.org/10.1016/s0955-0674(01)00301-5,"‘Hard’ and ‘soft’ principles defining the structure, function and regulation of keratin intermediate filaments",Coulombe
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT82,[3],"Langbein L, Rogers MA, Winter H, et al. 2001. J Biol Chem. The catalog of human hair keratins. I. Expression of the nine type I members in the hair follicle.",10.1074/jbc.m103305200,https://doi.org/10.1074/jbc.m103305200,The Catalog of Human Hair Keratins,Langbein
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL12B,[1],Trinchieri G. 2003. Nature Reviews Immunology. Interleukin-12 and the regulation of innate resistance and adaptive immunity.,10.1038/nri1001,https://doi.org/10.1038/nri1001,Interleukin-12 and the regulation of innate resistance and adaptive immunity,Trinchieri
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL12B,[2],"Vignali DA, Kuchroo VK. 2012. Nature Immunology. IL-12 family cytokines: immunological playmakers.",10.1038/ni.2366,https://doi.org/10.1038/ni.2366,IL-12 family cytokines: immunological playmakers,Vignali
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL12B,[3],"Colombo MP, Trinchieri G. 2002. Nature Reviews Cancer. Interleukin-12 in anti-tumor immunity and immunotherapy.",10.1016/s1359-6101(01)00032-6,https://doi.org/10.1016/s1359-6101(01)00032-6,Interleukin-12 in anti-tumor immunity and immunotherapy,Colombo
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL12B,[4],"Teng MW, et al. 2015. Nature Reviews Drug Discovery. Targeting IL-12 and IL-23 cytokines: from bench to bedside.",10.1016/j.ddstr.2006.08.004,https://doi.org/10.1016/j.ddstr.2006.08.004,Targeting the p40 cytokines interleukin (IL)-12 and IL-23 in Crohn's disease,Veldman
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[1],"Tomko RJ Jr, Hochstrasser M. 2013. Molecular Biology and Evolution. Molecular architecture and assembly of the eukaryotic proteasome.",10.1146/annurev-biochem-060410-150257,https://doi.org/10.1146/annurev-biochem-060410-150257,Molecular Architecture and Assembly of the Eukaryotic Proteasome,Tomko
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[2],"Ciechanover A, Kwon YT. 2015. Cell Research. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.",10.1038/emm.2014.117,https://doi.org/10.1038/emm.2014.117,Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies,Ciechanover
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[3],Adams J. 2004. Cancer Cell. The proteasome: a suitable antineoplastic target.,10.1038/nrc1361,https://doi.org/10.1038/nrc1361,The proteasome: a suitable antineoplastic target,Adams
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[4],"Vogel C, Marcotte EM. 2012. Nature Reviews Cancer. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses.",10.1038/nrg3185,https://doi.org/10.1038/nrg3185,Insights into the regulation of protein abundance from proteomic and transcriptomic analyses,Vogel
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMB7,[5],"Kisselev AF, van der Linden WA, Overkleeft HS. 2012. Chemical Biology. Proteasome inhibitors: an expanding army attacking a unique target.",10.1016/j.chembiol.2012.01.003,https://doi.org/10.1016/j.chembiol.2012.01.003,Proteasome Inhibitors: An Expanding Army Attacking a Unique Target,Kisselev
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[1],"Clevers H, Nusse R. 2012. Cell. Wnt/β-Catenin Signaling and Disease.",10.1016/j.cell.2012.05.012,https://doi.org/10.1016/j.cell.2012.05.012,Wnt/β-Catenin Signaling and Disease,Clevers
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[2],Compton CC. 2007. J Clin Oncol. Optimal Pathologic Staging: Defining Stage II Disease.,10.1158/1078-0432.ccr-07-1398,https://doi.org/10.1158/1078-0432.ccr-07-1398,Optimal Pathologic Staging: Defining Stage II Disease,Compton
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[3],"Franko J, et al. 2012. Ann Surg Oncol. Prognostic Value of Peritoneal Cancer Index and Small Bowel Involvement for Patients With Colorectal Carcinomatosis.",10.1245/s10434-009-0610-6,https://doi.org/10.1245/s10434-009-0610-6,CT Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis,Yan
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[4],"Van Cutsem E, et al. 2016. Ann Oncol. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.",10.1093/annonc/mdy355.001,https://doi.org/10.1093/annonc/mdy355.001,Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer ; A JSMO - ESMO initiative,Yoshino
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[5],"Longley DB, et al. 2003. Nat Rev Cancer. 5-Fluorouracil: mechanisms of action and clinical strategies.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[6],"Quail DF, Joyce JA. 2013. Nat Med. Microenvironmental regulation of tumor progression and metastasis.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_3,[7],"Gajewski TF, et al. 2013. Nat Immunol. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.",10.1016/j.coi.2013.02.009,https://doi.org/10.1016/j.coi.2013.02.009,Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment,Gajewski
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--MRGPRX2,[1],"Tatemoto K, Nozaki Y, Tsuda R, et al. 2006. Proc Natl Acad Sci U S A. Peptide histidine isoleucine and tryptase stimulate the release of histamine from human skin mast cells through activation of Mas-related gene X2.",10.3410/f.718012742.793480350,https://doi.org/10.3410/f.718012742.793480350,Faculty Opinions recommendation of β-Defensins activate human mast cells via Mas-related gene X2.,Stevens
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--MRGPRX2,[2],"Lembo PM, Grazzini E, Groblewski T, et al. 2002. Proc Natl Acad Sci U S A. Proenkephalin A gene products activate a new family of sensory neuron--specific GPCRs.",10.1038/nn815,https://doi.org/10.1038/nn815,Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs,Lembo
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRTAP9-3,[1],"Shimomura Y, Wajid M, Petukhova L, Kurban M, Christiano AM. 2010. Human Molecular Genetics. Mutations in the keratin-associated protein 9-3 (KRTAP9-3) gene underlie autosomal dominant woolly hair.",10.1016/j.ajhg.2010.02.025,https://doi.org/10.1016/j.ajhg.2010.02.025,"Autosomal-Dominant Woolly Hair Resulting from Disruption of Keratin 74 (KRT74), a Potential Determinant of Human Hair Texture",Shimomura
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRTAP9-3,[2],"Rogers MA, Langbein L, Praetzel-Wunder S, Winter H, Schweizer J. 2006. Journal of Investigative Dermatology. Human hair keratin-associated proteins (KAPs).",10.1016/s0074-7696(06)51006-x,https://doi.org/10.1016/s0074-7696(06)51006-x,Human Hair Keratin‐Associated Proteins (KAPs),Rogers
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IFNA10,[1],"Pestka S, Krause CD, Walter MR. 2004. Cytokine Growth Factor Rev. Interferons, interferon-like cytokines, and their receptors.",10.1111/j.0105-2896.2004.00204.x,https://doi.org/10.1111/j.0105-2896.2004.00204.x,"Interferons, interferon‐like cytokines, and their receptors",Pestka
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IFNA10,[2],"Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. J Biol Chem. Interferons at age 50: past, current and future impact on biomedicine.",10.1038/nrd2422,https://doi.org/10.1038/nrd2422,"Interferons at age 50: past, current and future impact on biomedicine",Borden
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IFNA10,[3],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IFNA10,[4],"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S, Goodale A, Lee Y, Ali LD, Jiang G, Lubonja R, Harrington WF, Strickland M, Wu T, Hawes DC, Zhivich VA, Wyatt MR, Kalani Z, Chang JJ, Okamoto M, Stegmaier K, Golub TR, Boehm JS, Vazquez F, Root DE, Hahn WC, Tsherniak A. 2017. Cell. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.1038/ng.3984,https://doi.org/10.1038/ng.3984,Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells,Meyers
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_1,[1],"Hechtman JF, Polydorides AD. 2012. Histopathological features of colorectal carcinomas. Gastroenterol Clin North Am. 41(3): 629-49.",10.3410/f.717973188.793470321,https://doi.org/10.3410/f.717973188.793470321,Faculty Opinions recommendation of Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.,Harpaz
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_1,[2],National Comprehensive Cancer Network. 2021. Rectal Cancer (Version 6.2021).,10.6004/jnccn.2007.0081,https://doi.org/10.6004/jnccn.2007.0081,Rectal Cancer,_
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_1,[3],"Topalian SL, Taube JM, Anders RA, Pardoll DM. 2016. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 16(5): 275-87.",10.1038/nrc.2016.36,https://doi.org/10.1038/nrc.2016.36,Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy,Topalian
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_1,[4],"Ribas A, Wolchok JD. 2018. Cancer immunotherapy using checkpoint blockade. Science. 359(6382): 1350-5.",10.1126/science.aar4060,https://doi.org/10.1126/science.aar4060,Cancer immunotherapy using checkpoint blockade,Ribas
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_1,[5],"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19(11): 1423-37.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_1,[6],"Balkwill FR, Capasso M, Hagemann T. 2012. The tumor microenvironment at a glance. J Cell Sci. 125(Pt 23): 5591-6.",10.1242/jcs.116392,https://doi.org/10.1242/jcs.116392,The tumor microenvironment at a glance,Balkwill
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[1],"Siegel RL, Miller KD, Jemal A. 2020. CA Cancer J Clin. Colorectal cancer statistics, 2020.",10.3322/caac.21590,https://doi.org/10.3322/caac.21590,"Cancer statistics, 2020",Siegel
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[2],Compton CC. 2006. Arch Pathol Lab Med. Optimal pathologic staging: defining stage II disease.,10.1158/1078-0432.ccr-07-1398,https://doi.org/10.1158/1078-0432.ccr-07-1398,Optimal Pathologic Staging: Defining Stage II Disease,Compton
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[3],"Jayne DG, Fook S, Loi C, Seow-Choen F. 2002. Br J Surg. Peritoneal carcinomatosis from colorectal cancer.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[4],"Glynne-Jones R, Wyrwicz L, Tiret E, et al. 2017. Ann Oncol. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",10.1093/annonc/mdx224,https://doi.org/10.1093/annonc/mdx224,"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Glynne-Jones
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[5],"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Nat Rev Cancer. Cancer drug resistance: an evolving paradigm.",10.1038/nrc3599,https://doi.org/10.1038/nrc3599,Cancer drug resistance: an evolving paradigm,Holohan
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[6],"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. 2014. Ann Oncol. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_20,[7],"Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. 2006. Ann Oncol. Epidemiology and management of liver metastases from colorectal cancer.",10.1097/01.sla.0000217629.94941.cf,https://doi.org/10.1097/01.sla.0000217629.94941.cf,Epidemiology and Management of Liver Metastases From Colorectal Cancer,Manfredi
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SDR9C7,[1],"Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, Favia AD, Duarte RG, Jörnvall H, Kavanagh KL, Kedishvili N, Kisiela M, Maser E, Mindnich R, Orchard S, Penning TM, Thornton JM, Adamski J, Oppermann U. 2009. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact. 178(1-3):94-8.",10.1016/j.cbi.2008.10.040,https://doi.org/10.1016/j.cbi.2008.10.040,The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative,Persson
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SDR9C7,[2],"Kisiela M, Faust A, Ebert B, Maser E, Scheidig AJ. 2012. Crystal structure of human SDR9C7, a short-chain dehydrogenase/reductase involved in retinoid metabolism. Chem Biol Interact. 195(2):139-47.",10.2210/pdb5ojg/pdb,https://doi.org/10.2210/pdb5ojg/pdb,Crystal structure of the dehydrogenase/reductase SDR family member 4 (DHRS4) from Caenorhabditis elegans,Scheidig
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SDR9C7,[3],"Bushue N, Wan YJ. 2010. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 62(13):1285-98.",10.1016/j.addr.2010.07.003,https://doi.org/10.1016/j.addr.2010.07.003,Retinoid pathway and cancer therapeutics,Bushue
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SDR9C7,[4],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 163(6):1515-26.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SDR9C7,[5],"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S, Goodale A, Lee Y, Ali LD, Jiang G, Lubonja R, Harrington WF, Strickland M, Wu T, Hawes DC, Zhivich VA, Wyatt MR, Kalani Z, Chang JJ, Okamoto M, Stegmaier K, Golub TR, Boehm JS, Vazquez F, Root DE, Hahn WC, Tsherniak A. 2017. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 49(12):1779-1784.",10.1038/ng.3984,https://doi.org/10.1038/ng.3984,Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells,Meyers
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SS18L2,[1],"Aizawa, H., Hu, S. C., Bobb, K., Balakrishnan, K., Ince, G., Gurevich, I., ... & Snyder, S. H. (2004). The Journal of Neuroscience, 24(43), 9658-9669. Dendrite development regulated by CREST, a calcium-regulated transcriptional activator.",10.1126/science.1089845,https://doi.org/10.1126/science.1089845,"Dendrite Development Regulated by CREST, a Calcium-Regulated Transcriptional Activator",Aizawa
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SS18L2,[2],"Qiu, Z., & Ghosh, A. (2008). Neuron, 60(1), 101-112. A calcium-dependent switch in a CREST-BRG1 complex regulates activity-dependent gene expression.",10.1016/j.neuron.2008.09.040,https://doi.org/10.1016/j.neuron.2008.09.040,A Calcium-Dependent Switch in a CREST-BRG1 Complex Regulates Activity-Dependent Gene Expression,Qiu
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SS18L2,[3],"Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., ... & Moffat, J. (2015). Cell, 162(4), 675-687. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SS18L2,[4],"Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., ... & Sabatini, D. M. (2015). Science, 350(6264), 1096-1101. Identification and characterization of essential genes in the human genome.",10.1126/science.aac7041,https://doi.org/10.1126/science.aac7041,Identification and characterization of essential genes in the human genome,Wang
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ZP2,[1],"Lefièvre L, Conner SJ, Salpekar A, et al. 2004. Human Reproduction. Four zona pellucida glycoproteins are expressed in the human.",10.1093/humrep/deh301,https://doi.org/10.1093/humrep/deh301,Four zona pellucida glycoproteins are expressed in the human,Lefievre
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ZP2,[2],"Rankin TL, Coleman JS, Epifano O, et al. 2003. Developmental Biology. Fertility and taxon-specific sperm binding persist after replacement of mouse sperm receptors with human homologs.",10.1016/s1534-5807(03)00195-3,https://doi.org/10.1016/s1534-5807(03)00195-3,Fertility and Taxon-Specific Sperm Binding Persist after Replacement of Mouse Sperm Receptors with Human Homologs,Rankin
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ZP2,[3],"Domcke S, Sinha R, Levine DA, et al. 2013. Nature Communications. Evaluating cell lines as tumour models by comparison of genomic profiles.",10.1038/ncomms3126,https://doi.org/10.1038/ncomms3126,Evaluating cell lines as tumour models by comparison of genomic profiles,Domcke
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_0,[1],"Fearon ER, Vogelstein B. 1990. Cell. A genetic model for colorectal tumorigenesis.",10.1016/0092-8674(90)90186-i,https://doi.org/10.1016/0092-8674(90)90186-i,A genetic model for colorectal tumorigenesis,Fearon
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_0,[2],"Punt CJ, Koopman M, Vermeulen L. 2017. Nat Rev Clin Oncol. From tumour heterogeneity to advances in precision treatment of colorectal cancer.",10.1038/nrclinonc.2016.171,https://doi.org/10.1038/nrclinonc.2016.171,From tumour heterogeneity to advances in precision treatment of colorectal cancer,Punt
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_0,[3],"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Nat Rev Cancer. Cancer drug resistance: an evolving paradigm.",10.1038/nrc3599,https://doi.org/10.1038/nrc3599,Cancer drug resistance: an evolving paradigm,Holohan
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_0,[4],"Quail DF, Joyce JA. 2013. Nat Med. Microenvironmental regulation of tumor progression and metastasis.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_0,[5],"Benson AB, Venook AP, Al-Hawary MM, et al. 2018. J Natl Compr Canc Netw. NCCN Guidelines Insights: Colon Cancer, Version 2.2018.",10.6004/jnccn.2019.0102,https://doi.org/10.6004/jnccn.2019.0102,"Erratum to: NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018: J Natl Compr Canc Netw 2018;16(10):1171–1182.",
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_0,[6],"Compton CC, Fielding LP, Burgart LJ, et al. 2000. Cancer. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.",10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t,https://doi.org/10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t,American Joint Committee on Cancer prognostic factors consensus conference,Compton
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[1],"Siegel RL, Miller KD, Jemal A. 2020. CA Cancer J Clin. Colorectal cancer statistics, 2020.",10.3322/caac.21590,https://doi.org/10.3322/caac.21590,"Cancer statistics, 2020",Siegel
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[2],Compton CC. 2007. Arch Pathol Lab Med. Optimal pathologic staging: defining stage II disease.,10.1158/1078-0432.ccr-07-1398,https://doi.org/10.1158/1078-0432.ccr-07-1398,Optimal Pathologic Staging: Defining Stage II Disease,Compton
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[3],National Comprehensive Cancer Network. 2021. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer.,10.6004/jnccn.2007.0025,https://doi.org/10.6004/jnccn.2007.0025,NCCN Invasive Breast Cancer Clinical Practice Guidelines in Oncology,_
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[4],"Chabner BA, Roberts TG Jr. 2005. N Engl J Med. Chemotherapy and the war on cancer.",10.1038/nrc1529,https://doi.org/10.1038/nrc1529,Chemotherapy and the war on cancer,Chabner
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[5],"Baskar R, Lee KA, Yeo R, Yeoh KW. 2012. J Med Radiat Sci. Cancer and radiation therapy: current advances and future directions.",10.7150/ijms.3635,https://doi.org/10.7150/ijms.3635,Cancer and Radiation Therapy: Current Advances and Future Directions,Baskar
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[6],"Glynne-Jones R, Wyrwicz L, Tiret E, et al. 2017. Ann Oncol. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",10.1093/annonc/mdx224,https://doi.org/10.1093/annonc/mdx224,"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Glynne-Jones
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[7],Gray H. 1918. Anatomy of the Human Body. The Large Intestine.,10.5962/bhl.title.20311,https://doi.org/10.5962/bhl.title.20311,Anatomy of the human body,Gray
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_19,[8],"American Joint Committee on Cancer. 2017. AJCC Cancer Staging Manual, 8th Edition.",10.1007/978-0-387-88441-7,https://doi.org/10.1007/978-0-387-88441-7,AJCC Cancer Staging Manual,"{'name': 'American Joint Committee on Cancer', 'sequence': 'first', 'affiliation': []}"
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[1],"Clevers H, Nusse R. 2012. Cell. Wnt/β-Catenin Signaling and Disease.",10.1016/j.cell.2012.05.012,https://doi.org/10.1016/j.cell.2012.05.012,Wnt/β-Catenin Signaling and Disease,Clevers
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[2],Fearon ER. 2011. Nature Reviews Cancer. Molecular genetics of colorectal cancer.,10.1146/annurev-pathol-011110-130235,https://doi.org/10.1146/annurev-pathol-011110-130235,Molecular Genetics of Colorectal Cancer,Fearon
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[3],Compton CC. 2007. Archives of Pathology & Laboratory Medicine. Updated Protocol for the Examination of Specimens From Patients With Carcinomas of the Colon and Rectum.,10.5858/2000-124-1016-upfteo,https://doi.org/10.5858/2000-124-1016-upfteo,"Updated Protocol for the Examination of Specimens From Patients With Carcinomas of the Colon and Rectum, Excluding Carcinoid Tumors, Lymphomas, Sarcomas, and Tumors of the Vermiform Appendix",Compton
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[4],"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Nature Reviews Cancer. Cancer drug resistance: an evolving paradigm.",10.1038/nrc3599,https://doi.org/10.1038/nrc3599,Cancer drug resistance: an evolving paradigm,Holohan
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[5],"Le DT, Uram JN, Wang H, et al. 2015. New England Journal of Medicine. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.",10.1056/nejmc1510353,https://doi.org/10.1056/nejmc1510353,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[6],Folkman J. 2007. Nature Reviews Drug Discovery. Angiogenesis: an organizing principle for drug discovery?,10.1038/nrd2115,https://doi.org/10.1038/nrd2115,Angiogenesis: an organizing principle for drug discovery?,Folkman
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_5,[7],"Quail DF, Joyce JA. 2013. Nature Medicine. Microenvironmental regulation of tumor progression and metastasis.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[3],"Van Cutsem, E., Cervantes, A., & Nordlinger, B. (2014). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25(suppl_3), iii1-iii9.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[4],"Le, D. T., Uram, J. N., & Wang, H. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmc1510353,https://doi.org/10.1056/nejmc1510353,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[5],"Compton, C. C. (2006). Prognostic factors in cancer. In Prognostic Factors in Cancer (pp. 43-66). Wiley-Liss.",10.3816/ccc.2002.n.020,https://doi.org/10.3816/ccc.2002.n.020,Pathologic Prognostic Factors in the Recurrence of Rectal Cancer,Compton
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[6],"Jayne, D. G., Fook, S., & Loi, C. (2002). Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery, 89(12), 1545-1550.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[7],"Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30.",10.3322/caac.21590,https://doi.org/10.3322/caac.21590,"Cancer statistics, 2020",Siegel
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[8],"Franko, J., Shi, Q., & Meyers, J. P. (2012). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17(12), 1709-1719.",10.1016/s1470-2045(16)30500-9,https://doi.org/10.1016/s1470-2045(16)30500-9,Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database,Franko
0,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[1],"Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E. 2007. Effects of beta-glucans on the immune system. Medicina (Kaunas). 43(8):597-606.",10.3390/medicina43080076,https://doi.org/10.3390/medicina43080076,Effects of ß-glucans on the immune system,Akramienė
1,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[2],"Beutler B. 2000. Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr Opin Microbiol. 3(1):23-28.",10.1016/s1369-5274(99)00046-6,https://doi.org/10.1016/s1369-5274(99)00046-6,"Endotoxin, Toll-like receptor 4, and the afferent limb of innate immunity",Beutler
2,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[3],"Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell. 140(6):805-820.",10.1016/j.cell.2010.01.022,https://doi.org/10.1016/j.cell.2010.01.022,Pattern Recognition Receptors and Inflammation,Takeuchi
3,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[4],"Kawai T, Akira S. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 34(5):637-650.",10.1016/j.immuni.2011.05.006,https://doi.org/10.1016/j.immuni.2011.05.006,Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity,Kawai
4,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[5],Dinarello CA. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 27:519-550.,10.1146/annurev.immunol.021908.132612,https://doi.org/10.1146/annurev.immunol.021908.132612,Immunological and Inflammatory Functions of the Interleukin-1 Family,Dinarello
5,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[6],"Chan GC, Chan WK, Sze DM. 2009. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol. 2:25.",10.1186/1756-8722-2-25,https://doi.org/10.1186/1756-8722-2-25,The effects of β-glucan on human immune and cancer cells,Chan
6,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[7],"Serbina NV, Pamer EG. 2006. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 7(3):311-317.",10.1038/ni1309,https://doi.org/10.1038/ni1309,Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2,Serbina
7,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[8],Nathan C. 2006. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 6(3):173-182.,10.1038/nri1785,https://doi.org/10.1038/nri1785,Neutrophils and immunity: challenges and opportunities,Nathan
8,experiments/trained_immunity/ai_messages/high_complexity--training_betaglucan,[9],"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. 2008. Functions of natural killer cells. Nat Immunol. 9(5):503-510.",10.1038/ni1582,https://doi.org/10.1038/ni1582,Functions of natural killer cells,Vivier
0,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[1],"Raetz CR, Whitfield C. 2002. Annual Review of Biochemistry. Lipopolysaccharide endotoxins.",10.1146/annurev.biochem.71.110601.135414,https://doi.org/10.1146/annurev.biochem.71.110601.135414,Lipopolysaccharide Endotoxins,Raetz
1,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[2],"Pålsson-McDermott EM, O'Neill LA. 2004. Trends in Immunology. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.",10.1111/j.1365-2567.2004.01976.x,https://doi.org/10.1111/j.1365-2567.2004.01976.x,"Signal transduction by the lipopolysaccharide receptor, Toll‐like receptor‐4",Pålsson‐McDermott
2,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[3],"Lu YC, Yeh WC, Ohashi PS. 2008. Annual Review of Immunology. LPS/TLR4 signal transduction pathway.",10.1016/j.cyto.2008.01.006,https://doi.org/10.1016/j.cyto.2008.01.006,LPS/TLR4 signal transduction pathway,Lu
3,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[4],"Biswas SK, Lopez-Collazo E. 2009. Immunology Letters. Endotoxin tolerance: new mechanisms, molecules and clinical significance.",10.1016/j.it.2009.07.009,https://doi.org/10.1016/j.it.2009.07.009,"Endotoxin tolerance: new mechanisms, molecules and clinical significance",Biswas
4,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[5],"Foster SL, Medzhitov R. 2009. Nature Immunology. Gene-specific control of the TLR-induced inflammatory response.",10.1016/j.clim.2008.08.015,https://doi.org/10.1016/j.clim.2008.08.015,Gene-specific control of the TLR-induced inflammatory response,Foster
5,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[6],"Wang J, Oberley-Deegan R, Wang S, Nikrad M, Funk CJ, Hartshorn KL, Mason RJ. 2009. Journal of Immunology. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-λ1) in response to influenza A infection.",10.4049/jimmunol.182.3.1296,https://doi.org/10.4049/jimmunol.182.3.1296,Differentiated Human Alveolar Type II Cells Secrete Antiviral IL-29 (IFN-λ1) in Response to Influenza A Infection,Wang
6,experiments/trained_immunity/ai_messages/high_complexity--training_LPS,[7],"Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN. 2013. Nature. The TLR4 antagonist Eritoran protects mice from lethal influenza infection.",10.1038/nature12118,https://doi.org/10.1038/nature12118,The TLR4 antagonist Eritoran protects mice from lethal influenza infection,Shirey
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ANKLE2,[1],"Brachner A, Foisner R. 2011. Nucleus. ANKLE2, a new nuclear envelope protein involved in human primary microcephaly.",10.1042/bst20110724,https://doi.org/10.1042/bst20110724,Evolvement of LEM proteins as chromatin tethers at the nuclear periphery,Brachner
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ANKLE2,[2],"Hussain MS, Baig SM, Neumann S, et al. 2013. Am J Hum Genet. A truncating mutation of CEP135 causes primary microcephaly and disturbed centrosomal function.",10.1016/j.ajhg.2012.03.016,https://doi.org/10.1016/j.ajhg.2012.03.016,A Truncating Mutation of CEP135 Causes Primary Microcephaly and Disturbed Centrosomal Function,Hussain
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ANKLE2,[3],"De Vos WH, Houben F, Kamps M, et al. 2011. Biochim Biophys Acta. Repetitive disruptions of the nuclear envelope invoke temporary loss of cellular compartmentalization in laminopathies.",10.1093/hmg/ddr344,https://doi.org/10.1093/hmg/ddr344,Repetitive disruptions of the nuclear envelope invoke temporary loss of cellular compartmentalization in laminopathies,De Vos
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--ANKLE2,[4],"Shay JW, Wright WE. 2011. Nat Rev Drug Discov. Telomerase therapeutics for cancer: challenges and new directions.",10.1038/nrd2081,https://doi.org/10.1038/nrd2081,Telomerase therapeutics for cancer: challenges and new directions,Shay
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GTF3C1,[1],"Lefebvre O, et al. 1992. Cell. Human TFIID Binds to Promoter TATA Boxes Via a Highly Conserved Subunit.",10.1111/j.1742-4658.2006.05468.x,https://doi.org/10.1111/j.1742-4658.2006.05468.x,FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2,Wierstra
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GTF3C1,[2],"Hsieh YJ, et al. 1999. Genes Dev. Structure and function of the BTB domain in the Drosophila GAGA factor.",10.1007/s004270050202,https://doi.org/10.1007/s004270050202,Comparison of the GAGA factor genes of Drosophila melanogaster and Drosophila virilis reveals high conservation of GAGA factor structure beyond the BTB/POZ and DNA-binding domains,Lintermann
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GTF3C1,[3],"DeBerardinis RJ, et al. 2008. Cell Metab. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.",10.1016/j.cmet.2007.10.002,https://doi.org/10.1016/j.cmet.2007.10.002,The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation,DeBerardinis
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GTF3C1,[4],"Pavon-Eternod M, et al. 2013. Oncogene. tRNA over-expression in breast cancer and functional consequences.",10.1093/nar/gkp787,https://doi.org/10.1093/nar/gkp787,tRNA over-expression in breast cancer and functional consequences,Pavon-Eternod
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_6,[1],"Compton CC, Fielding LP, Burgart LJ, et al. 2000. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739-57.",10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t,https://doi.org/10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t,American Joint Committee on Cancer prognostic factors consensus conference,Compton
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_6,[2],"Jayne DG, Fook S, Loi C, Seow-Choen F. 2002. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545-50.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_6,[3],National Comprehensive Cancer Network. 2021. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_6,[4],"Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74.",10.1016/j.cell.2011.02.013,https://doi.org/10.1016/j.cell.2011.02.013,Hallmarks of Cancer: The Next Generation,Hanahan
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_6,[5],"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423-37.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--FAM71C,[1],NCBI Gene. FAM71C family with sequence similarity 71 member C [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/283871,10.1007/978-3-319-67199-4_102580,https://doi.org/10.1007/978-3-319-67199-4_102580,NM_020820 (NCBI Reference Sequence for Homo sapiens Prex1 cDNA) / NM_177782 (NCBI Reference Sequence for Mus musculus Prex1 cDNA),
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--FAM71C,[2],"Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., ... & Tsherniak, A. (2017). Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nature genetics, 49(12), 1779-1784.",10.1038/ng.3984,https://doi.org/10.1038/ng.3984,Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells,Meyers
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--FAM71C,[3],"Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., ... & Moffat, J. (2015). High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell, 163(6), 1515-1526.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--AGAP5,[1],"Nie, Z., & Randazzo, P. A. (2006). Arf GAPs and membrane traffic. Journal of Cell Science, 119(Pt 7), 1203-1211.",10.1242/jcs.02924,https://doi.org/10.1242/jcs.02924,Arf GAPs and membrane traffic,Nie
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--AGAP5,[2],"Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., ... & Moffat, J. (2015). High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell, 163(6), 1515-1526.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TIMM29,[1],Mick et al. 2012. J Biol Chem. The mitochondrial import machinery has multiple connections to the respiratory chain.,10.1016/j.bbabio.2012.12.004,https://doi.org/10.1016/j.bbabio.2012.12.004,The mitochondrial protein import machinery has multiple connections to the respiratory chain,Kulawiak
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TIMM29,[2],Chacinska et al. 2009. Nat Rev Mol Cell Biol. Importing mitochondrial proteins: machineries and mechanisms.,10.1016/j.cell.2009.08.005,https://doi.org/10.1016/j.cell.2009.08.005,Importing Mitochondrial Proteins: Machineries and Mechanisms,Chacinska
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TIMM29,[3],Zong et al. 2016. Nat Rev Cancer. Mitochondria in cancer.,10.1038/nrc3365,https://doi.org/10.1038/nrc3365,Mitochondria and cancer,Wallace
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TIMM29,[4],Hanahan et al. 2011. Cell. Hallmarks of cancer: the next generation.,10.1016/j.cell.2011.02.013,https://doi.org/10.1016/j.cell.2011.02.013,Hallmarks of Cancer: The Next Generation,Hanahan
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TIMM29,[5],Wallace et al. 2010. Nat Rev Cancer. Mitochondria and cancer: Warburg addressed.,10.1101/sqb.2005.70.035,https://doi.org/10.1101/sqb.2005.70.035,Mitochondria and Cancer: Warburg Addressed,WALLACE
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TIMM29,[6],Green et al. 2004. Science. The pathophysiology of mitochondrial cell death.,10.1126/science.1099320,https://doi.org/10.1126/science.1099320,The Pathophysiology of Mitochondrial Cell Death,Green
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR3A3,[1],"Buck L, Axel R. 1991. Cell. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition.",10.1016/0092-8674(91)90418-x,https://doi.org/10.1016/0092-8674(91)90418-x,A novel multigene family may encode odorant receptors: A molecular basis for odor recognition,Buck
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR3A3,[2],"Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. 2013. Frontiers in Oncology. Expression profile of ectopic olfactory receptors determined by deep sequencing.",10.1371/journal.pone.0055368,https://doi.org/10.1371/journal.pone.0055368,Expression Profile of Ectopic Olfactory Receptors Determined by Deep Sequencing,Flegel
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR3A3,[3],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL7A,[1],"Wool, I. G. (1996). The Journal of Biological Chemistry. The structure and function of eukaryotic ribosomes.",10.1007/978-1-4612-4884-2_22,https://doi.org/10.1007/978-1-4612-4884-2_22,Studies of the Structure of Eukaryotic (Mammalian) Ribosomes,Wool
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL7A,[2],"Xue, S., & Barna, M. (2012). Nature Reviews Molecular Cell Biology. Specialized ribosomes: a new frontier in gene regulation and organismal biology.",10.1038/nrm3359,https://doi.org/10.1038/nrm3359,Specialized ribosomes: a new frontier in gene regulation and organismal biology,Xue
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL7A,[3],"Pelletier, J., Thomas, G., & Volarević, S. (2018). Nature Reviews Cancer. Ribosome biogenesis in cancer: new players and therapeutic avenues.",10.1038/nrc.2017.104,https://doi.org/10.1038/nrc.2017.104,Ribosome biogenesis in cancer: new players and therapeutic avenues,Pelletier
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL7A,[4],"Hart, T., & Moffat, J. (2016). Nature Reviews Genetics. BAGEL: a computational framework for identifying essential genes from pooled library screens.",10.1186/s12859-016-1015-8,https://doi.org/10.1186/s12859-016-1015-8,BAGEL: a computational framework for identifying essential genes from pooled library screens,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL7A,[5],"Shalem, O., Sanjana, N. E., & Zhang, F. (2015). Nature Reviews Genetics. High-throughput functional genomics using CRISPR-Cas9.",10.1038/nrg3899,https://doi.org/10.1038/nrg3899,High-throughput functional genomics using CRISPR–Cas9,Shalem
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HAUS4,[1],"Uehara R, et al. 2009. Nature. Human augmin complex plays a critical role in the assembly of the acentrosomal spindle microtubule array during mitosis.",10.1073/pnas.0901587106,https://doi.org/10.1073/pnas.0901587106,The augmin complex plays a critical role in spindle microtubule generation for mitotic progression and cytokinesis in human cells,Uehara
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HAUS4,[2],"Goshima G, et al. 2008. Science. Augmin: a protein complex required for centrosome-independent microtubule generation within the spindle.",10.1083/jcb.200711053,https://doi.org/10.1083/jcb.200711053,Augmin: a protein complex required for centrosome-independent microtubule generation within the spindle,Goshima
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HAUS4,[3],"Hanahan D, Weinberg RA. 2011. Cell. Hallmarks of cancer: the next generation.",10.1016/j.cell.2011.02.013,https://doi.org/10.1016/j.cell.2011.02.013,Hallmarks of Cancer: The Next Generation,Hanahan
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HAUS4,[4],Kaelin WG Jr. 2005. N Engl J Med. The concept of synthetic lethality in the context of anticancer therapy.,10.1038/nrc1691,https://doi.org/10.1038/nrc1691,The Concept of Synthetic Lethality in the Context of Anticancer Therapy,Kaelin
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HAUS4,[5],"Hart T, et al. 2015. Science. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities.",10.3410/f.725961145.793520856,https://doi.org/10.3410/f.725961145.793520856,Faculty Opinions recommendation of High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.,Kumar
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HAUS4,[6],"Shalem O, et al. 2014. Science. Genome-scale CRISPR-Cas9 knockout screening in human cells.",10.3410/f.718206642.793489428,https://doi.org/10.3410/f.718206642.793489428,Faculty Opinions recommendation of Genome-scale CRISPR-Cas9 knockout screening in human cells.,Beck
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NOC3L,[1],Entrez Gene: NOC3L nucleolar complex associated 3 homolog (S. cerevisiae),10.1016/s0378-1119(97)00564-7,https://doi.org/10.1016/s0378-1119(97)00564-7,The DUG gene of Drosophila melanogaster encodes a structural and functional homolog of the S. cerevisiae SUG1 predicted ATPase associated with the 26S proteasome,Mounkes
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NOC3L,[2],"Lawrence MS, et al. (2014) Nature. Discovery and saturation analysis of cancer genes across 21 tumour types.",10.3410/f.718228166.793490063,https://doi.org/10.3410/f.718228166.793490063,Faculty Opinions recommendation of Discovery and saturation analysis of cancer genes across 21 tumour types.,Copeland
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NOC3L,[3],"Davoli T, et al. (2013) Cell Reports. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.",10.1016/j.cell.2013.10.011,https://doi.org/10.1016/j.cell.2013.10.011,Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome,Davoli
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NOC3L,[4],"Hart T, et al. (2015) Science. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities.",10.3410/f.725961145.793520856,https://doi.org/10.3410/f.725961145.793520856,Faculty Opinions recommendation of High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.,Kumar
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NOC3L,[5],"Meyers RM, et al. (2017) Cell. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.3410/f.732049442.793551364,https://doi.org/10.3410/f.732049442.793551364,Faculty Opinions recommendation of Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.,Smedley
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL37A,[1],"Wool IG, Chan YL, Glück A. 1995. Nucleic Acids Res. Structure and evolution of mammalian ribosomal proteins.",10.1139/o95-101,https://doi.org/10.1139/o95-101,Structure and evolution of mammalian ribosomal proteins,Wool
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL37A,[2],"Pelletier J, Thomas G, Volarević S. 2018. Nat Rev Cancer. Ribosome biogenesis in cancer: new players and therapeutic avenues.",10.1038/nrc.2017.104,https://doi.org/10.1038/nrc.2017.104,Ribosome biogenesis in cancer: new players and therapeutic avenues,Pelletier
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL37A,[3],"Chen X, et al. 2018. Oncol Rep. RPL37A promotes tumorigenesis through an RPL37A-HMGA1-TIMP1 positive feedback loop in human breast cancer.",10.3892/or.2021.7959,https://doi.org/10.3892/or.2021.7959,LINC00649 promotes bladder cancer malignant progression by regulating the miR‑15a‑5p/HMGA1 axis,Chen
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL37A,[4],"Hart T, et al. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.3410/f.725961145.793520856,https://doi.org/10.3410/f.725961145.793520856,Faculty Opinions recommendation of High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.,Kumar
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL37A,[5],"Meyers RM, et al. 2017. Cell. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.3410/f.732049442.793551364,https://doi.org/10.3410/f.732049442.793551364,Faculty Opinions recommendation of Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.,Smedley
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL37A,[6],"Wang T, et al. 2015. Science. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.",10.3410/f.727280568.793543393,https://doi.org/10.3410/f.727280568.793543393,Faculty Opinions recommendation of Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.,Lazo
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KIF2B,[1],"Mennella, V., Rogers, G. C., Rogers, S. L., Buster, D. W., Vale, R. D., & Sharp, D. J. (2005). Molecular Biology of the Cell, 16(7), 3195-3209. Functionally distinct kinesin-13 family members cooperate to regulate microtubule dynamics during interphase.",10.1038/ncb1222,https://doi.org/10.1038/ncb1222,Functionally distinct kinesin-13 family members cooperate to regulate microtubule dynamics during interphase,Mennella
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KIF2B,[2],"Hirokawa, N., Noda, Y., Tanaka, Y., & Niwa, S. (2009). Nature Reviews Molecular Cell Biology, 10(10), 682-696. Kinesin superfamily motor proteins and intracellular transport.",10.1038/nrm2774,https://doi.org/10.1038/nrm2774,Kinesin superfamily motor proteins and intracellular transport,Hirokawa
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KIF2B,[3],"Zhang, Y., Wang, J., & Wang, Z. (2018). Oncology Letters, 15(6), 8749-8754. KIF2B, a novel oncogene, promotes cell proliferation and migration in hepatocellular carcinoma.",10.3892/ol.2018.9843,https://doi.org/10.3892/ol.2018.9843,miR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5,Wang
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KIF2B,[4],"Hart, T., & Moffat, J. (2016). Nature Reviews Genetics, 17(5), 300-312. BAGEL: a computational framework for identifying essential genes from pooled library screens.",10.1186/s12859-016-1015-8,https://doi.org/10.1186/s12859-016-1015-8,BAGEL: a computational framework for identifying essential genes from pooled library screens,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KIF2B,[5],"Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., ... & Tsherniak, A. (2017). Cell, 168(1-2), 890-903. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.3410/f.732049442.793551364,https://doi.org/10.3410/f.732049442.793551364,Faculty Opinions recommendation of Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.,Smedley
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KIF2B,[6],"Shalem, O., Sanjana, N. E., & Zhang, F. (2015). Nature Reviews Genetics, 16(3), 167-178. High-throughput functional genomics using CRISPR-Cas9.",10.1038/nrg3899,https://doi.org/10.1038/nrg3899,High-throughput functional genomics using CRISPR–Cas9,Shalem
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDST4,[1],"Aikawa J, Grobe K, Tsujimoto M, Esko JD. 2001. Glycobiology. Essential N-deacetylase/N-sulfotransferase enzymes for heparan sulfate biosynthesis.",10.1074/jbc.m009606200,https://doi.org/10.1074/jbc.m009606200,Multiple Isozymes of Heparan Sulfate/Heparin GlcNAcN-Deacetylase/GlcN N-Sulfotransferase,Aikawa
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDST4,[2],"Sarrazin S, Lamanna WC, Esko JD. 2011. Cold Spring Harb Perspect Biol. Heparan sulfate proteoglycans.",10.1101/cshperspect.a004952,https://doi.org/10.1101/cshperspect.a004952,Heparan Sulfate Proteoglycans,Sarrazin
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDST4,[3],"Iozzo RV, Sanderson RD. 2011. FEBS J. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.",10.1111/j.1582-4934.2010.01236.x,https://doi.org/10.1111/j.1582-4934.2010.01236.x,"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis",Iozzo
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDST4,[4],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDST4,[5],"Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC, Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey-Prevot B, Root DE, Sabatini DM, Taipale J, Perrimon N, Bernards R. 2006. Nat Methods. Minimizing the risk of reporting false positives in large-scale RNAi screens.",10.1038/nmeth1006-777,https://doi.org/10.1038/nmeth1006-777,Minimizing the risk of reporting false positives in large-scale RNAi screens,Echeverri
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDUFB3,[1],"Carroll J, Fearnley IM, Skehel JM, Shannon RJ, Hirst J, Walker JE. 2006. Proc Natl Acad Sci U S A. Bovine complex I is a complex of 45 different subunits.",10.1074/jbc.m607135200,https://doi.org/10.1074/jbc.m607135200,Bovine Complex I Is a Complex of 45 Different Subunits,Carroll
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDUFB3,[2],Hirst J. 2013. Annu Rev Biochem. Mitochondrial complex I.,10.1146/annurev-biochem-070511-103700,https://doi.org/10.1146/annurev-biochem-070511-103700,Mitochondrial Complex I,Hirst
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDUFB3,[3],"Zong WX, Rabinowitz JD, White E. 2016. Nat Rev Cancer. Mitochondria and Cancer.",10.1016/j.molcel.2016.02.011,https://doi.org/10.1016/j.molcel.2016.02.011,Mitochondria and Cancer,Zong
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDUFB3,[4],"Vander Heiden MG, Cantley LC, Thompson CB. 2009. Science. Understanding the Warburg effect: the metabolic requirements of cell proliferation.",10.1126/science.1160809,https://doi.org/10.1126/science.1160809,Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,Vander Heiden
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDUFB3,[5],"Pavlova NN, Thompson CB. 2016. Cell Metab. The Emerging Hallmarks of Cancer Metabolism.",10.1016/j.cmet.2015.12.006,https://doi.org/10.1016/j.cmet.2015.12.006,The Emerging Hallmarks of Cancer Metabolism,Pavlova
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--NDUFB3,[6],"Zhang J, Pavlova NN, Thompson CB. 2017. Cell Metab. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine.",10.15252/embj.201696151,https://doi.org/10.15252/embj.201696151,"Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine",Zhang
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR5T2,[1],"Buck L, Axel R. 1991. Cell. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition.",10.1016/0092-8674(91)90418-x,https://doi.org/10.1016/0092-8674(91)90418-x,A novel multigene family may encode odorant receptors: A molecular basis for odor recognition,Buck
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR5T2,[2],"Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. 2013. Frontiers in Physiology. Expression profile of ectopic olfactory receptors determined by deep sequencing.",10.1371/journal.pone.0055368,https://doi.org/10.1371/journal.pone.0055368,Expression Profile of Ectopic Olfactory Receptors Determined by Deep Sequencing,Flegel
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR5T2,[3],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[1],"Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).",10.1001/jama.2016.0289,https://doi.org/10.1001/jama.2016.0289,Developing a New Definition and Assessing New Clinical Criteria for Septic Shock,Shankar-Hari
1,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[2],"Kell DB, Pretorius E. 2014. Front Pharmacol. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.",10.1039/c3mt00347g,https://doi.org/10.1039/c3mt00347g,"Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells",Kell
2,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[3],Ziegler-Heitbrock L. 2007. Immunobiology. The CD14+ CD16+ blood monocytes: their role in infection and inflammation.,10.1189/jlb.0806510,https://doi.org/10.1189/jlb.0806510,The CD14+ CD16+ blood monocytes: their role in infection and inflammation,Ziegler-Heitbrock
3,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[4],"Docke WD, Randow F, Syrbe U, et al. 1997. Nat Med. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.",10.1038/nm0697-678,https://doi.org/10.1038/nm0697-678,Monocyte deactivation in septic patients: Restoration by IFN-γ treatment,Döcke
4,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[5],"Rhodes A, Evans LE, Alhazzani W, et al. 2017. Intensive Care Med. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.",10.1007/s00134-008-1089-5,https://doi.org/10.1007/s00134-008-1089-5,Comment on “Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008” by Dellinger et al.,Spoelstra - de Man
5,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[6],"Cecconi M, De Backer D, Antonelli M, et al. 2018. Intensive Care Med. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine.",10.1007/s00134-014-3525-z,https://doi.org/10.1007/s00134-014-3525-z,Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine,Cecconi
6,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_hyperinflammation,[7],"Annane D, Bellissant E, Bollaert PE, et al. 2009. JAMA. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.",10.1001/jama.2009.815,https://doi.org/10.1001/jama.2009.815,Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults,Annane
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DCTN3,[1],"Schroer, T.A. (2004) Traffic. Dynactin.",10.1016/b0-12-443710-9/00187-3,https://doi.org/10.1016/b0-12-443710-9/00187-3,Dynactin,Schroer
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DCTN3,[2],"Zhang, Y. et al. (2015) Oncotarget. Overexpression of DCTN3 promotes cell proliferation in breast cancer.",10.18632/oncotarget.8119,https://doi.org/10.18632/oncotarget.8119,MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer,Tan
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DCTN3,[3],"Winzeler, E.A. et al. (1999) Science. Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis.",10.1002/047084664x.ch14,https://doi.org/10.1002/047084664x.ch14,Functional Analysis of the Yeast Genome by Precise Deletion and Parallel Phenotypic Characterization,Winzeler
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DCTN3,[4],"Hart, T. et al. (2015) Cell. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.3410/f.725961145.793520856,https://doi.org/10.3410/f.725961145.793520856,Faculty Opinions recommendation of High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.,Kumar
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[1],"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. 2017. Neurology. Neurofibromatosis type 1.",10.1038/nrdp.2017.4,https://doi.org/10.1038/nrdp.2017.4,Neurofibromatosis type 1,Gutmann
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[2],"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[3],"Omuro A, DeAngelis LM. 2013. JAMA. Glioblastoma and other malignant gliomas: a clinical review.",10.1001/jama.2013.280319,https://doi.org/10.1001/jama.2013.280319,Glioblastoma and Other Malignant Gliomas,Omuro
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[4],"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1056/nejmoa043330,https://doi.org/10.1056/nejmoa043330,Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,Stupp
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--CCT5,[1],"Kubota H, Hynes G, Willison K. 1995. The chaperonin containing t-complex polypeptide 1 (TCP-1). Multisubunit machinery assisting in protein folding and assembly in the eukaryotic cytosol. Eur J Biochem. The eight-subunit chaperonin containing TCP-1.",10.1007/978-3-642-85252-7_11,https://doi.org/10.1007/978-3-642-85252-7_11,The chaperonin containing t-complex polypeptide 1 (TCP-1),Kubota
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--CCT5,[2],"Yokota S, Yanagi H, Yura T, Kubota H. 1999. Cytosolic chaperonin-containing t-complex polypeptide 1 changes the content of a particular subunit species concomitant with substrate binding and folding activities during the cell cycle. Eur J Biochem. Cell cycle-dependent expression of the chaperonin containing TCP-1.",10.1046/j.1432-1327.2001.02393.x,https://doi.org/10.1046/j.1432-1327.2001.02393.x,Cytosolic chaperonin‐containing t‐complex polypeptide 1 changes the content of a particular subunit species concomitant with substrate binding and folding activities during the cell cycle,Yokota
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--CCT5,[3],"Guest ST, Kratche ZR, Bollig-Fischer A, Haddad R, Ethier SP. 2015. Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes. Exp Cell Res. Essentiality of TRiC/CCT subunits in breast cancer cells.",10.1016/j.yexcr.2015.02.005,https://doi.org/10.1016/j.yexcr.2015.02.005,"Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes",Guest
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--CCT5,[4],"Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. The hallmarks of cancer.",10.1016/j.cell.2011.02.013,https://doi.org/10.1016/j.cell.2011.02.013,Hallmarks of Cancer: The Next Generation,Hanahan
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--CCT5,[5],"Fletcher DA, Mullins RD. 2010. Cell mechanics and the cytoskeleton. Nature. The role of the cytoskeleton in cell mechanics.",10.1038/nature08908,https://doi.org/10.1038/nature08908,Cell mechanics and the cytoskeleton,Fletcher
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--CCT5,[6],"Yam AY, Xia Y, Lin HT, Burlingame A, Gerstein M, Frydman J. 2008. Defining the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies. Nat Struct Mol Biol. The TRiC/CCT interactome and its role in protein folding.",10.1038/nsmb.1515,https://doi.org/10.1038/nsmb.1515,Defining the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies,Yam
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[1],"Ohgaki H, Kleihues P. 2009. Clinical Neuropathology. Genetic pathways to primary and secondary glioblastoma.",10.2353/ajpath.2007.070011,https://doi.org/10.2353/ajpath.2007.070011,Genetic Pathways to Primary and Secondary Glioblastoma,Ohgaki
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[2],"Samuels Y, et al. 2004. Science. High frequency of mutations of the PIK3CA gene in human cancers.",10.3410/f.1004498.210508,https://doi.org/10.3410/f.1004498.210508,Faculty Opinions recommendation of High frequency of mutations of the PIK3CA gene in human cancers.,Der
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[3],"Hegi ME, et al. 2005. New England Journal of Medicine. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[4],"Stupp R, et al. 2005. New England Journal of Medicine. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[5],"Janku F, et al. 2018. Nature Reviews Clinical Oncology. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.",10.1200/jco.2011.36.1196,https://doi.org/10.1200/jco.2011.36.1196,PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations,Janku
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT25,[1],"Schweizer J, Bowden PE, Coulombe PA, et al. 2006. J Cell Biol. New consensus nomenclature for mammalian keratins.",10.1083/jcb.200603161,https://doi.org/10.1083/jcb.200603161,New consensus nomenclature for mammalian keratins,Schweizer
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT25,[2],"Moll R, Divo M, Langbein L. 2008. Histochem Cell Biol. The human keratins: biology and pathology.",10.1007/s00418-008-0435-6,https://doi.org/10.1007/s00418-008-0435-6,The human keratins: biology and pathology,Moll
0,experiments/mouse_immunology/ai_messages/high_complexity--YUMM_1_7,[1],"Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. 2016. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. 29(5):590-7.",10.1111/pcmr.12498,https://doi.org/10.1111/pcmr.12498,The <scp>YUMM</scp> lines: a series of congenic mouse melanoma cell lines with defined genetic alterations,Meeth
1,experiments/mouse_immunology/ai_messages/high_complexity--YUMM_1_7,[2],National Cancer Institute. 2021. Melanoma Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq,10.1093/jnci/96.18.1355,https://doi.org/10.1093/jnci/96.18.1355,"Stat Bite: Treatment Trials in the PDQ Clinical Trials Database, by Phase",
2,experiments/mouse_immunology/ai_messages/high_complexity--YUMM_1_7,[3],"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. 2015. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35 Suppl:S185-S198.",10.1016/j.semcancer.2015.03.004,https://doi.org/10.1016/j.semcancer.2015.03.004,Immune evasion in cancer: Mechanistic basis and therapeutic strategies,Vinay
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT26,[1],"Moll R, Divo M, Langbein L. 2008. The human keratins: biology and pathology. Histochemistry and Cell Biology.",10.1007/s00418-008-0435-6,https://doi.org/10.1007/s00418-008-0435-6,The human keratins: biology and pathology,Moll
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--KRT26,[2],"Shimomura Y, Wajid M, Petukhova L, Kurban M, Christiano AM. 2010. Autosomal-dominant woolly hair resulting from disruption of keratin 74 (KRT74), a potential determinant of human hair texture. American Journal of Human Genetics.",10.1016/j.ajhg.2010.02.025,https://doi.org/10.1016/j.ajhg.2010.02.025,"Autosomal-Dominant Woolly Hair Resulting from Disruption of Keratin 74 (KRT74), a Potential Determinant of Human Hair Texture",Shimomura
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DSPP,[1],"Yamakoshi Y, Hu JC, Fukae M, Zhang H, Simmer JP. 2005. Journal of Biological Chemistry. Dentin Sialophosphoprotein is Processed by MMP-2 and MMP-20 in vitro and in vivo.",10.1074/jbc.m607767200,https://doi.org/10.1074/jbc.m607767200,Dentin Sialophosphoprotein Is Processed by MMP-2 and MMP-20 in Vitro and in Vivo,Yamakoshi
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DSPP,[2],"Ogbureke KU, Fisher LW. 2004. Journal of Histochemistry & Cytochemistry. Expression of SIBLINGs and their partner MMPs in salivary glands.",10.1177/154405910408300902,https://doi.org/10.1177/154405910408300902,Expression of SIBLINGs and Their Partner MMPs in Salivary Glands,Ogbureke
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DSPP,[3],Masters JR. 2000. British Journal of Cancer. Human cancer cell lines: fact and fantasy.,10.1038/35043102,https://doi.org/10.1038/35043102,Human cancer cell lines: fact and fantasy,Masters
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HSPD1,[1],"Hansen JJ, et al. 2003. Nature Genetics. Missense mutations in the human mitochondrial chaperonin Hsp60 gene.",10.1007/s00439-002-0837-9,https://doi.org/10.1007/s00439-002-0837-9,Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter,Hansen
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HSPD1,[2],"Cappello F, et al. 2003. Cancer. HSP60 expression, new locations, functions, and perspectives for cancer diagnosis and therapy.",10.4161/cbt.7.6.6281,https://doi.org/10.4161/cbt.7.6.6281,"Hsp60 expression, new locations, functions, and perspectives for cancer diagnosis and therapy",Cappello
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HSPD1,[3],"Chandra D, et al. 2007. Cancer Research. Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death.",10.1128/mcb.24.15.6592-6607.2004,https://doi.org/10.1128/mcb.24.15.6592-6607.2004,Association of Active Caspase 8 with the Mitochondrial Membrane during Apoptosis: Potential Roles in Cleaving BAP31 and Caspase 3 and Mediating Mitochondrion-Endoplasmic Reticulum Cross Talk in Etoposide-Induced Cell Death,Chandra
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HSPD1,[4],"Ghosh JC, et al. 2010. Molecular and Cellular Biology. HSP60 regulation of tumor cell apoptosis.",10.1074/jbc.m705904200,https://doi.org/10.1074/jbc.m705904200,Hsp60 Regulation of Tumor Cell Apoptosis,Ghosh
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HSPD1,[5],"Desmetz C, et al. 2012. PLoS One. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.",10.1021/pr800130d,https://doi.org/10.1021/pr800130d,Proteomics-Based Identification of HSP60 as a Tumor-Associated Antigen in Early Stage Breast Cancer and Ductal Carcinoma <i>in situ</i>,Desmetz
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MUC16_MGMT_medium_methylated,[1],"Li J, Yen C, Liaw D, et al. 1997. Science. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.",10.1126/science.275.5308.1943,https://doi.org/10.1126/science.275.5308.1943,"<i>PTEN</i>
            , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer",Li
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MUC16_MGMT_medium_methylated,[2],"Gubbels JA, Belisle J, Onda M, et al. 2006. Cancer Res. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.",10.1186/1476-4598-5-50,https://doi.org/10.1186/1476-4598-5-50,"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors",Gubbels
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MUC16_MGMT_medium_methylated,[3],"Hegi ME, Diserens AC, Gorlia T, et al. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MUC16_MGMT_medium_methylated,[4],"Stupp R, Mason WP, van den Bent MJ, et al. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MUC16_MGMT_medium_methylated,[5],"Weller M, van den Bent M, Tonn JC, et al. 2017. Lancet Oncol. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.",10.1016/s1470-2045(17)30194-8,https://doi.org/10.1016/s1470-2045(17)30194-8,European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas,Weller
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--POLR3H,[1],"Hu, P., Wu, S., & Sun, Y. (2002). The Journal of Biological Chemistry, The 14.5-kDa Subunit of Human Translation Initiation Factor eIF3 Is the Homolog of the Yeast eIF3 Subunit p.",10.1074/jbc.274.39.27567,https://doi.org/10.1074/jbc.274.39.27567,The Saccharomyces cerevisiae HCR1 Gene Encoding a Homologue of the p35 Subunit of Human Translation Initiation Factor 3 (eIF3) Is a High Copy Suppressor of a Temperature-sensitive Mutation in the Rpg1p Subunit of Yeast eIF3,Valášek
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--POLR3H,[2],"White, R. J. (2005). Nature Reviews Molecular Cell Biology, RNA polymerases I and III, growth control and cancer.",10.1038/nrm1551,https://doi.org/10.1038/nrm1551,"RNA polymerases I and III, growth control and cancer",White
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PRPF19,[1],"Grote, M., Wolf, E., Will, C. L., Lemm, I., Agafonov, D. E., Schomburg, A., ... & Luhrmann, R. (2010). Molecular Cell, 37(2), 247-258. The DEAD-box helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.",10.1016/j.bbrc.2016.12.153,https://doi.org/10.1016/j.bbrc.2016.12.153,The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation,Nakata
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PRPF19,[2],"Zhang, N., Kaur, R., Akhter, S., Legerski, R. J. (2016). Oncotarget, 7(15), 20464-20479. C1D is a major effector of PRPF19 in response to DNA damage.",10.18632/oncotarget.6422,https://doi.org/10.18632/oncotarget.6422,Forkhead transcription factor FoxF1 interacts with Fanconi anemia protein complexes to promote DNA damage response,Pradhan
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PRPF19,[3],"Zhang, N., Kaur, R., Lu, X., Shen, X., Li, L., & Legerski, R. J. (2015). Oncogene, 34(8), 1068-1076. The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links.",10.1074/jbc.m508453200,https://doi.org/10.1074/jbc.m508453200,The Pso4 mRNA Splicing and DNA Repair Complex Interacts with WRN for Processing of DNA Interstrand Cross-links,Zhang
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PRPF19,[4],"Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., ... & Moffat, J. (2015). Science, 348(6237), 124-128. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PRPF19,[5],"Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., ... & Tsherniak, A. (2017). Cell, 168(4), 856-866. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.3410/f.732049442.793551364,https://doi.org/10.3410/f.732049442.793551364,Faculty Opinions recommendation of Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.,Smedley
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OPA1,[1],"Alexander C. Zambon, 2021, Frontiers in Cell and Developmental Biology, The Multifaceted Roles of OPA1 in Cancer",10.3389/fcell.2021.630161,https://doi.org/10.3389/fcell.2021.630161,The Multifaceted Roles of Primary Cilia in the Development of the Cerebral Cortex,Hasenpusch-Theil
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OPA1,[2],"Del Dotto V, Mishra P, Vidoni S, et al., 2017, Oncotarget, OPA1 Isoforms in the Hierarchical Organization of Mitochondrial Functions",10.1016/j.celrep.2017.05.073,https://doi.org/10.1016/j.celrep.2017.05.073,OPA1 Isoforms in the Hierarchical Organization of Mitochondrial Functions,Del Dotto
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OPA1,[3],"Lenaers G, Hamel C, Delettre C, et al., 2012, Human Molecular Genetics, Dominant Optic Atrophy",10.1006/mgme.2001.3278,https://doi.org/10.1006/mgme.2001.3278,OPA1 (Kjer Type) Dominant Optic Atrophy: A Novel Mitochondrial Disease,Delettre
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OPA1,[4],"Vyas S, Zaganjor E, Haigis MC, 2016, Cell, Mitochondria and Cancer",10.1016/j.cell.2016.07.002,https://doi.org/10.1016/j.cell.2016.07.002,Mitochondria and Cancer,Vyas
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OPA1,[5],"Zhang H, Zhang Y, Zhu X, et al., 2019, Journal of Cancer, OPA1 Overexpression is Associated with Poor Prognosis in Patients with Colorectal Cancer",10.3892/ol.2017.7049,https://doi.org/10.3892/ol.2017.7049,Overexpression of long non‑coding RNA colon cancer‑associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer,Zhang
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OPA1,[6],"Zhao X, Tian C, Puszyk WM, et al., 2013, Cancer Research, OPA1 Downregulation is Involved in Sorafenib-induced Apoptosis in Hepatocellular Carcinoma",10.1038/labinvest.2012.144,https://doi.org/10.1038/labinvest.2012.144,OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma,Zhao
0,experiments/mouse_immunology/ai_messages/high_complexity--Cyanide,[1],"Nicholls P, Kim JK. 1982. Biochimica et Biophysica Acta (BBA) - Bioenergetics. Sulphide as an inhibitor and electron donor for the cytochrome c oxidase system.",10.1016/0005-2728(81)90170-5,https://doi.org/10.1016/0005-2728(81)90170-5,Oxidation of sulphide by cytochrome aa3,Nicholls
1,experiments/mouse_immunology/ai_messages/high_complexity--Cyanide,[2],"Brown GC, Borutaite V. 2004. Biochemical Society Transactions. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols.",10.1016/j.bbabio.2004.03.016,https://doi.org/10.1016/j.bbabio.2004.03.016,"Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols",Brown
2,experiments/mouse_immunology/ai_messages/high_complexity--Cyanide,[3],"Alberts B, Johnson A, Lewis J, et al. 2002. Molecular Biology of the Cell. 4th edition. New York: Garland Science. Energy Conversion: Mitochondria and Chloroplasts.",10.1201/9781315735368-14,https://doi.org/10.1201/9781315735368-14,Energy Conversion: Mitochondria and Chloroplasts,Alberts
3,experiments/mouse_immunology/ai_messages/high_complexity--Cyanide,[4],"Lobo V, Patil A, Phatak A, Chandra N. 2010. Pharmacognosy Reviews. Free radicals, antioxidants and functional foods: Impact on human health.",10.4103/0973-7847.70902,https://doi.org/10.4103/0973-7847.70902,"Free radicals, antioxidants and functional foods: Impact on human health",Lobo
4,experiments/mouse_immunology/ai_messages/high_complexity--Cyanide,[5],Siesjo BK. 1992. Journal of Cerebral Blood Flow & Metabolism. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology.,10.3171/jns.1992.77.2.0169,https://doi.org/10.3171/jns.1992.77.2.0169,Pathophysiology and treatment of focal cerebral ischemia,Siesjö
5,experiments/mouse_immunology/ai_messages/high_complexity--Cyanide,[6],Baud FJ. 2007. Critical Care. Cyanide: critical issues in diagnosis and treatment.,10.1177/0960327107070566,https://doi.org/10.1177/0960327107070566,Cyanide: critical issues in diagnosis and treatment,Baud
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[1],"Gaffen SL, Jain R, Garg AV, Cua DJ. 2014. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nature Reviews Immunology.",10.1038/nri3707,https://doi.org/10.1038/nri3707,The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing,Gaffen
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[2],"Iwakura Y, Ishigame H, Saijo S, Nakae S. 2011. Functional specialization of interleukin-17 family members. Immunity.",10.1016/j.immuni.2011.02.012,https://doi.org/10.1016/j.immuni.2011.02.012,Functional Specialization of Interleukin-17 Family Members,Iwakura
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[3],"Wu X, Yang T, Liu X, Guo JN, Xie T, Ding Y, Lin M, Yang H. 2013. IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer. Tumour Biology.",10.1007/s13277-015-4372-4,https://doi.org/10.1007/s13277-015-4372-4,IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer,Wu
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[4],"Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. 2002. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood.",10.1182/blood.v99.6.2114,https://doi.org/10.1182/blood.v99.6.2114,Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism,Benchetrit
0,experiments/trained_immunity/ai_messages/high_complexity--tolerance_LPS,[1],"Raetz CR, Whitfield C. 2002. Annual Review of Biochemistry. Lipopolysaccharide endotoxins.",10.1146/annurev.biochem.71.110601.135414,https://doi.org/10.1146/annurev.biochem.71.110601.135414,Lipopolysaccharide Endotoxins,Raetz
1,experiments/trained_immunity/ai_messages/high_complexity--tolerance_LPS,[2],"Lu YC, Yeh WC, Ohashi PS. 2008. Immunity. LPS/TLR4 signal transduction pathway.",10.1016/j.cyto.2008.01.006,https://doi.org/10.1016/j.cyto.2008.01.006,LPS/TLR4 signal transduction pathway,Lu
2,experiments/trained_immunity/ai_messages/high_complexity--tolerance_LPS,[3],Mogensen TH. 2009. Clinical Microbiology Reviews. Pathogen recognition and inflammatory signaling in innate immune defenses.,10.1128/cmr.00046-08,https://doi.org/10.1128/cmr.00046-08,Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses,Mogensen
3,experiments/trained_immunity/ai_messages/high_complexity--tolerance_LPS,[4],"Biswas SK, Lopez-Collazo E. 2009. Immunological Reviews. Endotoxin tolerance: new mechanisms, molecules and clinical significance.",10.1016/j.it.2009.07.009,https://doi.org/10.1016/j.it.2009.07.009,"Endotoxin tolerance: new mechanisms, molecules and clinical significance",Biswas
4,experiments/trained_immunity/ai_messages/high_complexity--tolerance_LPS,[5],"Yao Z, Mates JM, Cheplowitz AM, Hammer LP, Maiseyeu A, Phillips GS, Wewers MD, Rajaram MV, Robinson JM, Anderson CL, Ganesan LP. 2016. Journal of Immunology. Blood-borne lipopolysaccharide is rapidly eliminated by liver sinusoidal endothelial cells via high-density lipoprotein.",10.4049/jimmunol.1600702,https://doi.org/10.4049/jimmunol.1600702,Blood-Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-Density Lipoprotein,Yao
5,experiments/trained_immunity/ai_messages/high_complexity--tolerance_LPS,[6],"Wang J, Li R, Peng Z, Hu B, Rao X, Li J. 2018. Frontiers in Immunology. Pathogen recognition receptors and endotoxin tolerance.",10.1016/j.dci.2014.04.018,https://doi.org/10.1016/j.dci.2014.04.018,"Pathogen recognition receptors in channel catfish: IV. Identification, phylogeny and expression analysis of peptidoglycan recognition proteins",Sun
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[1],"Levine AJ. 2020. Cell. p53: 30 years and 30,000 papers later.",10.2307/j.ctvwh8f9c.50,https://doi.org/10.2307/j.ctvwh8f9c.50,Mystery Woman Speaks 30 Years Later,
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[2],"Hegi ME, et al. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.3410/f.718384246.793495041,https://doi.org/10.3410/f.718384246.793495041,Faculty Opinions recommendation of MGMT gene silencing and benefit from temozolomide in glioblastoma.,Gilbert
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[3],Cancer Genome Atlas Research Network. 2008. Nature. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.,10.1038/nature07385,https://doi.org/10.1038/nature07385,Comprehensive genomic characterization defines human glioblastoma genes and core pathways,"{'name': 'The Cancer Genome Atlas Research Network', 'sequence': 'first', 'affiliation': []}"
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[4],"Furnari FB, et al. 2007. Genes Dev. Malignant astrocytic glioma: genetics, biology, and paths to treatment.",10.1101/gad.1596707,https://doi.org/10.1101/gad.1596707,"Malignant astrocytic glioma: genetics, biology, and paths to treatment",Furnari
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[5],"Stupp R, et al. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[1],NCBI Gene. (n.d.). H2BC1 histone cluster 1 H2B family member c [Homo sapiens (human)] - Gene - NCBI. Retrieved from https://www.ncbi.nlm.nih.gov/gene/85236,10.7717/peerj.6561/fig-1,https://doi.org/10.7717/peerj.6561/fig-1,Figure 1: Minimum-Spanning-Tree of 462 hemagglutinin gene sequences of “Old-World”-orthopoxviruses retrieved from NCBI (March 2018).,
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[2],"Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997). Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature, 389(6648), 251-260.",10.1038/38444,https://doi.org/10.1038/38444,Crystal structure of the nucleosome core particle at 2.8 Å resolution,Luger
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[3],"Bannister, A. J., & Kouzarides, T. (2011). Regulation of chromatin by histone modifications. Cell Research, 21(3), 381-395.",10.1038/cr.2011.22,https://doi.org/10.1038/cr.2011.22,Regulation of chromatin by histone modifications,Bannister
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[4],"Feinberg, A. P., & Tycko, B. (2004). The history of cancer epigenetics. Nature Reviews Cancer, 4(2), 143-153.",10.1038/nrc1279,https://doi.org/10.1038/nrc1279,The history of cancer epigenetics,Feinberg
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[5],"Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., ... & Moffat, J. (2015). High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell, 163(6), 1515-1526.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[6],"Kaelin Jr, W. G. (2005). The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer, 5(9), 689-698.",10.1038/nrc1691,https://doi.org/10.1038/nrc1691,The Concept of Synthetic Lethality in the Context of Anticancer Therapy,Kaelin
6,experiments/gene_essentiality_cancer/ai_messages/high_complexity--H2BC1,[7],"Xu, M., Long, C., Chen, X., Huang, C., Chen, S., & Zhu, B. (2010). Partitioning of histone H3-H4 tetramers during DNA replication-dependent chromatin assembly. Science, 328(5974), 94-98.",10.1126/science.1178994,https://doi.org/10.1126/science.1178994,Partitioning of Histone H3-H4 Tetramers During DNA Replication–Dependent Chromatin Assembly,Xu
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--AQP8,[1],"Agre P, Kozono D. 2003. Nature Reviews Molecular Cell Biology. Aquaporin water channels: molecular mechanisms for human diseases.",10.1016/s0014-5793(03)01083-4,https://doi.org/10.1016/s0014-5793(03)01083-4,Aquaporin water channels: molecular mechanisms for human diseases<sup>1</sup>,Agre
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--AQP8,[2],"Ishibashi K, Hara S, Kondo S. 2009. Pflugers Archiv: European Journal of Physiology. Aquaporin water channels in mammals.",10.1007/s10157-008-0118-6,https://doi.org/10.1007/s10157-008-0118-6,Aquaporin water channels in mammals,Ishibashi
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--AQP8,[3],"Papadopoulos MC, Saadoun S. 2015. British Journal of Cancer. Key roles of aquaporins in tumor biology.",10.1016/j.bbamem.2014.09.001,https://doi.org/10.1016/j.bbamem.2014.09.001,Key roles of aquaporins in tumor biology,Papadopoulos
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--AQP8,[4],"Wang J, Feng L, Zhu Z, Zheng M, Wang D, Chen Z, Sun H. 2015. Oncotarget. Aquaporin 8 mediates human esophageal cancer Eca-109 cell migration via the EGFR-Erk1/2 pathway.",10.18632/oncotarget.8576,https://doi.org/10.18632/oncotarget.8576,Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer,Zhu
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--S100A7A,[1],"Marenholz I, Heizmann CW, Fritz G. 2004. Biochem Biophys Res Commun. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature).",10.1016/j.bbrc.2004.07.096,https://doi.org/10.1016/j.bbrc.2004.07.096,S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature),Marenholz
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--S100A7A,[2],"Enerbäck C, Porter DA, Seth P, Sgroi D, Gaudet J, Weremowicz S, Morton CC, Schnitt S, Pitts RL, Stampl J, Barnhart K, Polyak K. 2002. Cancer Res. Psoriasin expression in mammary epithelial cells in vitro and in vivo.",10.1371/journal.pone.0053119,https://doi.org/10.1371/journal.pone.0053119,The Expression of Psoriasin (S100A7) and CD24 Is Linked and Related to the Differentiation of Mammary Epithelial Cells,Vegfors
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--S100A7A,[3],"Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F. 2012. Int J Cancer. S100A9 a new marker for monocytic human myeloid-derived suppressor cells.",10.1111/j.1365-2567.2012.03566.x,https://doi.org/10.1111/j.1365-2567.2012.03566.x,S100A9 a new marker for monocytic human myeloid-derived suppressor cells,Zhao
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--S100A7A,[4],"Alowami S, Qing G, Emberley E, Snell L, Watson PH. 2003. Mod Pathol. Psoriasin (S100A7) expression is altered during skin tumorigenesis.",10.1186/1471-5945-3-1,https://doi.org/10.1186/1471-5945-3-1,Psoriasin (S100A7) expression is altered during skin tumorigenesis,Alowami
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--S100A7A,[5],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Cell. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--S100A7A,[6],"Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. 2015. Science. Gene essentiality and synthetic lethality in haploid human cells.",10.1126/science.aac7557,https://doi.org/10.1126/science.aac7557,Gene essentiality and synthetic lethality in haploid human cells,Blomen
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--LGALS14,[1],"Liu FT, Rabinovich GA. 2005. Annual Review of Immunology. Galectins: Regulators of acute and chronic inflammation.",10.1111/j.1749-6632.2009.05131.x,https://doi.org/10.1111/j.1749-6632.2009.05131.x,Galectins: regulators of acute and chronic inflammation,Liu
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--LGALS14,[2],"Rabinovich GA, Croci DO. 2012. Nature Reviews Immunology. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer.",10.1016/j.immuni.2012.03.004,https://doi.org/10.1016/j.immuni.2012.03.004,Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer,Rabinovich
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--LGALS14,[3],"Hart T, Moffat J. 2016. Nature Reviews Genetics. BAGEL: a computational framework for identifying essential genes from pooled library screens.",10.1186/s12859-016-1015-8,https://doi.org/10.1186/s12859-016-1015-8,BAGEL: a computational framework for identifying essential genes from pooled library screens,Hart
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--LGALS14,[4],"Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. 2015. Science. Gene essentiality and synthetic lethality in haploid human cells.",10.1126/science.aac7557,https://doi.org/10.1126/science.aac7557,Gene essentiality and synthetic lethality in haploid human cells,Blomen
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[3],"Van Cutsem, E., & Cervantes, A. (2011). Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of Oncology, 22(suppl_6), vi61-vi63.",10.1093/annonc/mdq222,https://doi.org/10.1093/annonc/mdq222,Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment,Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[4],"Le, D. T., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409-413.",10.3410/f.727697784.793571316,https://doi.org/10.3410/f.727697784.793571316,Faculty Opinions recommendation of Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.,Berlin
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[5],"Meacham, C. E., & Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature, 501(7467), 328-337.",10.1038/nature12624,https://doi.org/10.1038/nature12624,Tumour heterogeneity and cancer cell plasticity,Meacham
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[6],"Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423-1437.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[7],"Franko, J., Shi, Q., & Meyers, J. P. (2012). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17(12), 1709-1719.",10.1016/s1470-2045(16)30500-9,https://doi.org/10.1016/s1470-2045(16)30500-9,Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database,Franko
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_16,[8],"Jayne, D. G., & Fook, S. (2002). Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery, 89(12), 1545-1550.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne
0,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[1],"Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).",10.1001/jama.2016.0289,https://doi.org/10.1001/jama.2016.0289,Developing a New Definition and Assessing New Clinical Criteria for Septic Shock,Shankar-Hari
1,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[2],"Arosio P, Ingrassia R, Cavadini P. 2009. Biochim Biophys Acta. Ferritins: A family of molecules for iron storage, antioxidation and more.",10.1016/j.bbagen.2008.09.004,https://doi.org/10.1016/j.bbagen.2008.09.004,"Ferritins: A family of molecules for iron storage, antioxidation and more",Arosio
2,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[3],"Weiss G, Goodnough LT. 2005. N Engl J Med. Anemia of Chronic Disease.",10.1056/nejmra041809,https://doi.org/10.1056/nejmra041809,Anemia of Chronic Disease,Weiss
3,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[4],"Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. 2010. J Leukoc Biol. Nomenclature of monocytes and dendritic cells in blood.",10.1182/blood-2010-02-258558,https://doi.org/10.1182/blood-2010-02-258558,Nomenclature of monocytes and dendritic cells in blood,Ziegler-Heitbrock
4,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[5],"Monneret G, Lepape A, Voirin N, et al. 2006. Crit Care Med. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.",10.1007/s00134-006-0204-8,https://doi.org/10.1007/s00134-006-0204-8,Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock,Monneret
5,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[6],"Hotchkiss RS, Monneret G, Payen D. 2013. Nat Rev Immunol. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.",10.1038/nri3552,https://doi.org/10.1038/nri3552,Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy,Hotchkiss
6,experiments/sepsis_treatment/ai_messages/high_complexity--sepsis_immunoparalysis,[7],"Litton E, Xiao J, Ho KM. 2013. JAMA. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials.",10.1136/bmj.f4822,https://doi.org/10.1136/bmj.f4822,Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials,Litton
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_17,[1],"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. 2014. Ann Oncol. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_17,[2],"Longley DB, Harkin DP, Johnston PG. 2003. Nat Rev Cancer. 5-fluorouracil: mechanisms of action and clinical strategies.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_17,[3],"Cunningham D, Humblet Y, Siena S, et al. 2004. N Engl J Med. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.",10.1056/nejmoa033025,https://doi.org/10.1056/nejmoa033025,Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,Cunningham
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_17,[4],"Le DT, Uram JN, Wang H, et al. 2015. N Engl J Med. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.",10.1007/s11725-015-0588-4,https://doi.org/10.1007/s11725-015-0588-4,PD-1 blockade in tumors with mismatch-repair deficiency,Aparicio
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_17,[5],Compton CC. 2007. Arch Pathol Lab Med. Prognostic factors in cancer: role of the pathologist.,10.3109/9781439807231-4,https://doi.org/10.3109/9781439807231-4,The role of the pathologist in assessing prognostic factors for breast cancer,
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_17,[6],"Chaffer CL, Weinberg RA. 2011. Science. A perspective on cancer cell metastasis.",10.1126/science.1203543,https://doi.org/10.1126/science.1203543,A Perspective on Cancer Cell Metastasis,Chaffer
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GPR78,[1],"Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. 2003. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Molecular Pharmacology 63(6):1256-1272.",10.1124/mol.63.6.1256,https://doi.org/10.1124/mol.63.6.1256,"The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints",Fredriksson
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GPR78,[2],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell 163(6):1515-1526.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MGMT_medium_methylated,[1],"Song MS, Salmena L, Pandolfi PP. 2012. Nature Reviews Molecular Cell Biology. The functions and regulation of the PTEN tumour suppressor.",10.1038/nrm3330,https://doi.org/10.1038/nrm3330,The functions and regulation of the PTEN tumour suppressor,Song
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MGMT_medium_methylated,[2],"Hegi ME, Diserens AC, Gorlia T, et al. 2005. New England Journal of Medicine. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MGMT_medium_methylated,[3],Cancer Genome Atlas Research Network. 2008. Nature. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.,10.1038/nature07385,https://doi.org/10.1038/nature07385,Comprehensive genomic characterization defines human glioblastoma genes and core pathways,"{'name': 'The Cancer Genome Atlas Research Network', 'sequence': 'first', 'affiliation': []}"
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MGMT_medium_methylated,[4],"Ostrom QT, Gittleman H, Liao P, et al. 2014. Neuro-Oncology. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.",10.1093/neuonc/nou223,https://doi.org/10.1093/neuonc/nou223,CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011,Ostrom
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MGMT_medium_methylated,[5],"Stupp R, Mason WP, van den Bent MJ, et al. 2005. New England Journal of Medicine. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
5,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_MGMT_medium_methylated,[6],"Wen PY, Reardon DA. 2016. Journal of Clinical Oncology. Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.",10.1038/nrneurol.2015.242,https://doi.org/10.1038/nrneurol.2015.242,"Progress in glioma diagnosis, classification and treatment",Wen
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--EIF2B3,[1],"Gomez E, Mohammad SS, Pavitt GD. 2002. Molecular Biology of the Cell. eIF2B, a mediator of general and gene-specific translational control.",10.1042/bst0331487,https://doi.org/10.1042/bst0331487,"eIF2B, a mediator of general and gene-specific translational control",Pavitt
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--EIF2B3,[2],"Pavitt GD, Ramaiah KVA, Kimball SR, Hinnebusch AG. 1998. Molecular and Cellular Biology. eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange.",10.1101/gad.12.4.514,https://doi.org/10.1101/gad.12.4.514,eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange,Pavitt
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--EIF2B3,[3],"Silvera D, Formenti SC, Schneider RJ. 2010. Nature Reviews Cancer. The role of protein synthesis regulation in cancer.",10.1038/nrc2824,https://doi.org/10.1038/nrc2824,Translational control in cancer,Silvera
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--EIF2B3,[4],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--EIF2B3,[5],Kaelin WG Jr. 2005. New England Journal of Medicine. The concept of synthetic lethality in the context of anticancer therapy.,10.1038/nrc1691,https://doi.org/10.1038/nrc1691,The Concept of Synthetic Lethality in the Context of Anticancer Therapy,Kaelin
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[1],National Comprehensive Cancer Network. (2021). Colon Cancer (Version 2.2021).,10.1007/978-3-030-64668-4_3,https://doi.org/10.1007/978-3-030-64668-4_3,Diet and Colon Cancer: A Comprehensive Review,Kulshrestha
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[3],"Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., ... & Nordlinger, B. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[4],"Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., ... & Taube, J. M. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmoa1500596,https://doi.org/10.1056/nejmoa1500596,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,Le
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[5],"Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423-1437.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[6],"Noy, R., & Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1), 49-61.",10.1016/j.immuni.2014.06.010,https://doi.org/10.1016/j.immuni.2014.06.010,Tumor-Associated Macrophages: From Mechanisms to Therapy,Noy
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[7],"Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews Cancer, 16(9), 582-598.",10.1038/nrc.2016.73,https://doi.org/10.1038/nrc.2016.73,The biology and function of fibroblasts in cancer,Kalluri
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[8],"Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275-292.",10.1016/j.cell.2011.09.024,https://doi.org/10.1016/j.cell.2011.09.024,Tumor Metastasis: Molecular Insights and Evolving Paradigms,Valastyan
8,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_15,[9],"Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., & Bouvier, A. M. (2006). Epidemiology and management of liver metastases from colorectal cancer. Annals of Surgery, 244(2), 254-259.",10.1097/01.sla.0000217629.94941.cf,https://doi.org/10.1097/01.sla.0000217629.94941.cf,Epidemiology and Management of Liver Metastases From Colorectal Cancer,Manfredi
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_8,[1],"Compton CC, Fielding LP, Burgart LJ, et al. 2000. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739-57.",10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t,https://doi.org/10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t,American Joint Committee on Cancer prognostic factors consensus conference,Compton
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_8,[2],"Siegel RL, Miller KD, Jemal A. 2020. Cancer statistics, 2020. CA Cancer J Clin 70:7-30.",10.3322/caac.21590,https://doi.org/10.3322/caac.21590,"Cancer statistics, 2020",Siegel
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_8,[3],"Benson AB, Venook AP, Al-Hawary MM, et al. 2018. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw 16:359-69.",10.6004/jnccn.2018.0021,https://doi.org/10.6004/jnccn.2018.0021,"NCCN Guidelines Insights: Colon Cancer, Version 2.2018",Benson
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_8,[4],"Punt CJ, Koopman M, Vermeulen L. 2017. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 14:235-46.",10.1038/nrclinonc.2016.171,https://doi.org/10.1038/nrclinonc.2016.171,From tumour heterogeneity to advances in precision treatment of colorectal cancer,Punt
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_8,[5],"Lee MS, Menter DG, Kopetz S. 2017. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. J Natl Compr Canc Netw 15:411-9.",10.6004/jnccn.2017.0038,https://doi.org/10.6004/jnccn.2017.0038,Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes,Lee
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR52W1,[1],"Niimura Y, Nei M. 2003. Evolution of olfactory receptor genes in the human genome. Proceedings of the National Academy of Sciences. 100(21): 12235-12240.",10.1073/pnas.1635157100,https://doi.org/10.1073/pnas.1635157100,Evolution of olfactory receptor genes in the human genome,Niimura
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR52W1,[2],"Buck L, Axel R. 1991. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell. 65(1): 175-187.",10.1016/0092-8674(91)90418-x,https://doi.org/10.1016/0092-8674(91)90418-x,A novel multigene family may encode odorant receptors: A molecular basis for odor recognition,Buck
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR52W1,[3],"Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. 2013. Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS One. 8(2): e55368.",10.1371/journal.pone.0055368,https://doi.org/10.1371/journal.pone.0055368,Expression Profile of Ectopic Olfactory Receptors Determined by Deep Sequencing,Flegel
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--OR52W1,[4],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 163(6): 1515-1526.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_9,[1],"Glynne-Jones R, Wyrwicz L, Tiret E, et al. 2017. Ann Oncol. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",10.1093/annonc/mdx224,https://doi.org/10.1093/annonc/mdx224,"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Glynne-Jones
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_9,[2],"Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. 2006. J Clin Oncol. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.",10.1002/bjs.5506,https://doi.org/10.1002/bjs.5506,Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer,Bujko
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_9,[3],"Gerard JP, Conroy T, Bonnetain F, et al. 2006. J Clin Oncol. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.",10.1200/jco.2006.06.7629,https://doi.org/10.1200/jco.2006.06.7629,Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203,Gérard
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_9,[4],"Sauer R, Becker H, Hohenberger W, et al. 2004. N Engl J Med. Preoperative versus postoperative chemoradiotherapy for rectal cancer.",10.1056/nejmoa040694,https://doi.org/10.1056/nejmoa040694,Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer,Sauer
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_9,[5],"Heald RJ, Ryall RD. 1986. Lancet. Recurrence and survival after total mesorectal excision for rectal cancer.",10.1016/s0140-6736(86)91510-2,https://doi.org/10.1016/s0140-6736(86)91510-2,RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCER,Heald
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_9,[6],"André T, Boni C, Navarro M, et al. 2009. J Clin Oncol. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.",10.1200/jco.2008.20.6771,https://doi.org/10.1200/jco.2008.20.6771,"Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial",André
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_14,[1],"Siegel RL, Miller KD, Jemal A. 2020. CA Cancer J Clin. Cancer statistics, 2020.",10.3322/caac.21590,https://doi.org/10.3322/caac.21590,"Cancer statistics, 2020",Siegel
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_14,[2],"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. 2014. Ann Oncol. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_14,[3],"Hanahan D, Weinberg RA. 2011. Cell. Hallmarks of cancer: the next generation.",10.1016/j.cell.2011.02.013,https://doi.org/10.1016/j.cell.2011.02.013,Hallmarks of Cancer: The Next Generation,Hanahan
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_14,[4],"Mehlen P, Puisieux A. 2006. Nat Rev Cancer. Metastasis: a question of life or death.",10.1038/nrc1886,https://doi.org/10.1038/nrc1886,Metastasis: a question of life or death,Mehlen
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SUPT16H,[1],"Orphanides G, Wu WH, Lane WS, Hampsey M, Reinberg D. 1999. Cell. The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins.",10.1038/22350,https://doi.org/10.1038/22350,The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins,Orphanides
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SUPT16H,[2],"García H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, Liu S, Morrison C, Gurova KV. 2013. Oncotarget. Facilitates chromatin transcription complex is an 'accelerator' of tumor transformation and potential marker and target of aggressive cancers.",10.1016/j.celrep.2013.06.013,https://doi.org/10.1016/j.celrep.2013.06.013,Facilitates Chromatin Transcription Complex Is an “Accelerator” of Tumor Transformation and Potential Marker and Target of Aggressive Cancers,Garcia
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SUPT16H,[3],"Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV. 2011. Proc Natl Acad Sci U S A. Curaxins: Anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.",10.1126/scitranslmed.3002530,https://doi.org/10.1126/scitranslmed.3002530,Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT,Gasparian
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SUPT16H,[4],"Safina A, Garcia H, Commane M, Guryanova O, Degan S, Kolesnikova K, Gurova KV. 2013. Oncotarget. Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells.",10.4161/cc.25452,https://doi.org/10.4161/cc.25452,Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells,Safina
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SUPT16H,[5],"Zhang Y, Zhang M, Wu J, Lei G, Li H. 2013. Biochem Biophys Res Commun. Transcriptional regulation of the Ufm1 conjugation system in response to disturbance of the endoplasmic reticulum homeostasis and inhibition of vesicle trafficking.",10.1371/journal.pone.0048587,https://doi.org/10.1371/journal.pone.0048587,Transcriptional Regulation of the Ufm1 Conjugation System in Response to Disturbance of the Endoplasmic Reticulum Homeostasis and Inhibition of Vesicle Trafficking,Zhang
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPL,[1],"Geuens T, Bouhy D, Timmerman V. 2016. The hnRNP family: insights into their role in health and disease. Human Genetics.",10.1007/s00439-016-1683-5,https://doi.org/10.1007/s00439-016-1683-5,The hnRNP family: insights into their role in health and disease,Geuens
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPL,[2],"Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J, Kolch W, Zender L, Karni R. 2014. Splicing factor hnRNP L regulates myeloid cell responses to lipopolysaccharide. Immunity.",10.1261/rna.042259.113,https://doi.org/10.1261/rna.042259.113,Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development,Shilo
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPL,[3],"Zhang J, Manley JL. 2013. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discovery.",10.1158/2159-8290.cd-13-0253,https://doi.org/10.1158/2159-8290.cd-13-0253,Misregulation of Pre-mRNA Alternative Splicing in Cancer,Zhang
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPL,[4],"Wang J, Guo Y, Chu H, Guan Y, Bi J, Wang B. 2013. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. International Journal of Molecular Sciences.",10.3390/ijms140510015,https://doi.org/10.3390/ijms140510015,"Multiple Functions of the RNA-Binding Protein HuR in Cancer Progression, Treatment Responses and Prognosis",Wang
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPL,[5],"Huang H, Zhang J, Harvey SE, Hu X, Cheng C. 2017. RNA G-quadruplex secondary structure promotes alternative splicing via the RNA-binding protein hnRNPF. Genes & Development.",10.1101/gad.305862.117,https://doi.org/10.1101/gad.305862.117,RNA G-quadruplex secondary structure promotes alternative splicing via the RNA-binding protein hnRNPF,Huang
5,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPL,[6],"Wang Z, Kayikci M, Briese M, Zarnack K, Luscombe NM, Rot G, Zupan B, Curk T, Ule J. 2010. iCLIP predicts the dual splicing effects of TIA-RNA interactions. PLoS Biology.",10.1371/journal.pbio.1000530,https://doi.org/10.1371/journal.pbio.1000530,iCLIP Predicts the Dual Splicing Effects of TIA-RNA Interactions,Wang
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GK2,[1],"Bairoch A, Apweiler R. 2000. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 28(1):45-48.",10.1093/nar/28.1.45,https://doi.org/10.1093/nar/28.1.45,The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000,Bairoch
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GK2,[2],"Nelson DL, Cox MM. 2017. Lehninger Principles of Biochemistry. 7th ed. W.H. Freeman and Company.",10.1002/bmb.2005.494033010419,https://doi.org/10.1002/bmb.2005.494033010419,"Lehninger principles of biochemistry (4th ed.): Nelson, D., and Cox, M.",Boyle
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--GK2,[3],"Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144(5):646-674.",10.1016/j.cell.2011.02.013,https://doi.org/10.1016/j.cell.2011.02.013,Hallmarks of Cancer: The Next Generation,Hanahan
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SLC25A2,[1],"Palmieri F. (2013) The mitochondrial transporter family SLC25: identification, properties and physiopathology. Molecular Aspects of Medicine 34(2-3): 465-484.",10.1016/j.mam.2012.05.005,https://doi.org/10.1016/j.mam.2012.05.005,"The mitochondrial transporter family SLC25: Identification, properties and physiopathology",Palmieri
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SLC25A2,[2],Pegg AE. (2009) Mammalian polyamine metabolism and function. IUBMB Life 61(9): 880-894.,10.1002/iub.230,https://doi.org/10.1002/iub.230,Mammalian polyamine metabolism and function,Pegg
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SLC25A2,[3],"Casero RA Jr, Marton LJ. (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nature Reviews Drug Discovery 6(5): 373-390.",10.1038/nrd2243,https://doi.org/10.1038/nrd2243,Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases,Casero
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--SLC25A2,[4],Seiler N. (2003) Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Current Drug Targets 4(7): 537-564.,10.2174/1389450033490885,https://doi.org/10.2174/1389450033490885,Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors,Seiler
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_NF1_MGMT_low_methylated,[1],"Furnari FB, Fenton T, Bachoo RM, et al. 2007. Cancer Cell. Malignant astrocytic glioma: genetics, biology, and paths to treatment.",10.1101/gad.1596707,https://doi.org/10.1101/gad.1596707,"Malignant astrocytic glioma: genetics, biology, and paths to treatment",Furnari
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_NF1_MGMT_low_methylated,[2],"Hegi ME, Diserens AC, Gorlia T, et al. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_NF1_MGMT_low_methylated,[3],"Ostrom QT, Gittleman H, Liao P, et al. 2014. Neuro Oncol. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.",10.1093/neuonc/nou223,https://doi.org/10.1093/neuonc/nou223,CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011,Ostrom
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_NF1_MGMT_low_methylated,[4],"Stupp R, Mason WP, van den Bent MJ, et al. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_NF1_MGMT_low_methylated,[5],"Alexander BM, Cloughesy TF. 2017. J Clin Oncol. Adult Glioblastoma.",10.1200/jco.2017.73.0119,https://doi.org/10.1200/jco.2017.73.0119,Adult Glioblastoma,Alexander
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_TP53_NF1_RB1_MGMT_medium_methylated,[1],"Stupp R, et al. 2005. New England Journal of Medicine. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_TP53_NF1_RB1_MGMT_medium_methylated,[2],"Furnari FB, et al. 2007. Genes & Development. Malignant astrocytic glioma: genetics, biology, and paths to treatment.",10.1101/gad.1596707,https://doi.org/10.1101/gad.1596707,"Malignant astrocytic glioma: genetics, biology, and paths to treatment",Furnari
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_TP53_NF1_RB1_MGMT_medium_methylated,[3],"Hegi ME, et al. 2005. New England Journal of Medicine. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[3],"Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., ... & Nordlinger, B. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[4],"Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., ... & Taube, J. M. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmoa1500596,https://doi.org/10.1056/nejmoa1500596,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,Le
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[5],"Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423-1437.",10.1038/nm.3394,https://doi.org/10.1038/nm.3394,Microenvironmental regulation of tumor progression and metastasis,Quail
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[6],"Noy, R., & Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1), 49-61.",10.1016/j.immuni.2014.06.010,https://doi.org/10.1016/j.immuni.2014.06.010,Tumor-Associated Macrophages: From Mechanisms to Therapy,Noy
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[7],"Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews Cancer, 16(9), 582-598.",10.1038/nrc.2016.73,https://doi.org/10.1038/nrc.2016.73,The biology and function of fibroblasts in cancer,Kalluri
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[8],"Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275-292.",10.1016/j.cell.2011.09.024,https://doi.org/10.1016/j.cell.2011.09.024,Tumor Metastasis: Molecular Insights and Evolving Paradigms,Valastyan
8,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_10,[9],"Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., & Bouvier, A. M. (2006). Epidemiology and management of liver metastases from colorectal cancer. Annals of Surgery, 244(2), 254-259.",10.1097/01.sla.0000217629.94941.cf,https://doi.org/10.1097/01.sla.0000217629.94941.cf,Epidemiology and Management of Liver Metastases From Colorectal Cancer,Manfredi
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL27,[1],"Wool, I. G., Chan, Y. L., & Glück, A. (1995). Structure and evolution of mammalian ribosomal proteins. Biochemistry and Cell Biology, 73(11-12), 933-947.",10.1139/o95-101,https://doi.org/10.1139/o95-101,Structure and evolution of mammalian ribosomal proteins,Wool
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL27,[2],"Xue, S., & Barna, M. (2012). Specialized ribosomes: a new frontier in gene regulation and organismal biology. Nature Reviews Molecular Cell Biology, 13(6), 355-369.",10.1038/nrm3359,https://doi.org/10.1038/nrm3359,Specialized ribosomes: a new frontier in gene regulation and organismal biology,Xue
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL27,[3],"Zhang, Y., Zhang, M., Yu, F., & Lu, S. (2019). Overexpression of ribosomal protein L27 predicts poor prognosis in colorectal cancer. Oncology Letters, 18(4), 3899-3904.",10.3892/ol.2018.7724,https://doi.org/10.3892/ol.2018.7724,Overexpression of flavin-containing monooxygenase 5 predicts poor prognosis in patients with colorectal cancer,Zhang
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL27,[4],"Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., ... & Davis, R. W. (1999). Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science, 285(5429), 901-906.",10.1126/science.285.5429.901,https://doi.org/10.1126/science.285.5429.901,"Functional Characterization of the
            <i>S. cerevisiae</i>
            Genome by Gene Deletion and Parallel Analysis",Winzeler
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RPL27,[5],"Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., ... & Moffat, J. (2015). High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell, 163(6), 1515-1526.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TMPRSS11F,[1],"Szabo R, Bugge TH. (2011) Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol. 27:213-35.",10.1146/annurev-cellbio-092910-154247,https://doi.org/10.1146/annurev-cellbio-092910-154247,Membrane-Anchored Serine Proteases in Vertebrate Cell and Developmental Biology,Szabo
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TMPRSS11F,[2],"Antalis TM, Bugge TH, Wu Q. (2011) Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci. 99:1-50.",10.1016/b978-0-12-385504-6.00001-4,https://doi.org/10.1016/b978-0-12-385504-6.00001-4,Membrane-Anchored Serine Proteases in Health and Disease,Antalis
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TMPRSS11F,[3],"Hart T, Moffat J. (2016) BAGEL: a computational framework for identifying essential genes from pooled library screens. BMC Bioinformatics. 17:164.",10.1186/s12859-016-1015-8,https://doi.org/10.1186/s12859-016-1015-8,BAGEL: a computational framework for identifying essential genes from pooled library screens,Hart
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--TMPRSS11F,[4],"Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. (2015) Gene essentiality and synthetic lethality in haploid human cells. Science. 350:1092-6.",10.1126/science.aac7557,https://doi.org/10.1126/science.aac7557,Gene essentiality and synthetic lethality in haploid human cells,Blomen
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[3],"Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., ... & Nordlinger, B. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[4],"Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., ... & Taube, J. M. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmoa1500596,https://doi.org/10.1056/nejmoa1500596,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,Le
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[5],"Meacham, C. E., & Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature, 501(7467), 328-337.",10.1038/nature12624,https://doi.org/10.1038/nature12624,Tumour heterogeneity and cancer cell plasticity,Meacham
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[6],"Compton, C. C. (2007). Optimal pathologic staging: defining stage II disease. Clinical Cancer Research, 13(22), 6862s-6870s.",10.1158/1078-0432.ccr-07-1398,https://doi.org/10.1158/1078-0432.ccr-07-1398,Optimal Pathologic Staging: Defining Stage II Disease,Compton
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[7],"Chaffer, C. L., & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 331(6024), 1559-1564.",10.1126/science.1203543,https://doi.org/10.1126/science.1203543,A Perspective on Cancer Cell Metastasis,Chaffer
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[8],"Jayne, D. G., Fook, S., Loi, C., & Seow-Choen, F. (2002). Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery, 89(12), 1545-1550.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[1],"Li J, Yen C, Liaw D, et al. 1997. Science. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.",10.1126/science.275.5308.1943,https://doi.org/10.1126/science.275.5308.1943,"<i>PTEN</i>
            , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer",Li
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[2],"Yarden Y, Sliwkowski MX. 2001. Nature Reviews Molecular Cell Biology. Untangling the ErbB signalling network.",10.1038/35052073,https://doi.org/10.1038/35052073,Untangling the ErbB signalling network,Yarden
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[3],"Kaina B, Christmann M, Naumann S, Roos WP. 2007. DNA Repair. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.",10.1016/j.dnarep.2007.03.008,https://doi.org/10.1016/j.dnarep.2007.03.008,"MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents",Kaina
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[4],"Hegi ME, Diserens AC, Gorlia T, et al. 2005. New England Journal of Medicine. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[5],"Furnari FB, Fenton T, Bachoo RM, et al. 2007. Genes & Development. Malignant astrocytic glioma: genetics, biology, and paths to treatment.",10.1101/gad.1596707,https://doi.org/10.1101/gad.1596707,"Malignant astrocytic glioma: genetics, biology, and paths to treatment",Furnari
5,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[6],"Stupp R, Mason WP, van den Bent MJ, et al. 2005. New England Journal of Medicine. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
6,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PTEN_EGFR_MGMT_high_methylated,[7],"Wen PY, Kesari S. 2008. New England Journal of Medicine. Malignant gliomas in adults.",10.1056/nejmra0708126,https://doi.org/10.1056/nejmra0708126,Malignant Gliomas in Adults,Wen
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RBX1,[1],"Zheng N, Schulman BA, Song L, et al. 2002. Nature. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.",10.2210/pdb1ldd/pdb,https://doi.org/10.2210/pdb1ldd/pdb,Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF Ubiquitin Ligase Complex,Zheng
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RBX1,[2],"Skaar JR, Pagan JK, Pagano M. 2013. Nat Rev Mol Cell Biol. Mechanisms and function of substrate recruitment by F-box proteins.",10.1038/nrm3582,https://doi.org/10.1038/nrm3582,Mechanisms and function of substrate recruitment by F-box proteins,Skaar
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RBX1,[3],"Nakayama KI, Nakayama K. 2006. Nat Rev Cancer. Ubiquitin ligases: cell-cycle control and cancer.",10.1038/nrc1881,https://doi.org/10.1038/nrc1881,Ubiquitin ligases: cell-cycle control and cancer,Nakayama
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RBX1,[4],"Meyers RM, Bryan JG, McFarland JM, et al. 2017. Nature. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.3410/f.732049442.793551364,https://doi.org/10.3410/f.732049442.793551364,Faculty Opinions recommendation of Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.,Smedley
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--RBX1,[5],"Hart T, Chandrashekhar M, Aregger M, et al. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PIK3CA_MGMT_high_methylated,[1],"Samuels Y, et al. 2004. Science. Mutant PIK3CA promotes cell growth and invasion of human cancer cells.",10.3410/f.1026480.335881,https://doi.org/10.3410/f.1026480.335881,Faculty Opinions recommendation of Mutant PIK3CA promotes cell growth and invasion of human cancer cells.,Kumar
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PIK3CA_MGMT_high_methylated,[2],"Hegi ME, et al. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.3410/f.718384246.793495041,https://doi.org/10.3410/f.718384246.793495041,Faculty Opinions recommendation of MGMT gene silencing and benefit from temozolomide in glioblastoma.,Gilbert
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PIK3CA_MGMT_high_methylated,[3],"Zhao HF, et al. 2017. Oncotarget. PIK3CA mutations promote glioma cell invasion and migration.",10.18632/oncotarget.23931,https://doi.org/10.18632/oncotarget.23931,"MiR-148a-3p suppresses cell proliferation, migration and invasion by targeting PIK3CA in human osteosarcoma cells",Wang
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_PIK3CA_MGMT_high_methylated,[4],"Roos WP, et al. 2007. Oncogene. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.",10.1038/sj.onc.1209785,https://doi.org/10.1038/sj.onc.1209785,Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine,Roos
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPK,[1],"Bomsztyk K, Denisenko O, Ostrowski J. 2004. Nucleic Acids Res. Heterogeneous nuclear ribonucleoprotein K: an abundant, conserved, and essential pre-mRNA-binding protein.",10.1074/jbc.271.44.27701,https://doi.org/10.1074/jbc.271.44.27701,"Zik1, a Transcriptional Repressor That Interacts with the Heterogeneous Nuclear Ribonucleoprotein Particle K Protein",Denisenko
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPK,[2],"Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI. 2006. Br J Cancer. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer.",10.1038/sj.bjc.6603349,https://doi.org/10.1038/sj.bjc.6603349,"Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer",Carpenter
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPK,[3],"Barboro P, Ferrari N, Balbi C. 2014. Cell Death Dis. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.",10.1016/j.canlet.2014.06.019,https://doi.org/10.1016/j.canlet.2014.06.019,Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression,Barboro
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPK,[4],"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. 2015. Science. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.",10.1016/j.cell.2015.11.015,https://doi.org/10.1016/j.cell.2015.11.015,High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,Hart
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--HNRNPK,[5],"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S, Goodale A, Lee Y, Ali LD, Jiang G, Lubonja R, Harrington WF, Strickland M, Wu T, Hawes DC, Zhivich VA, Wyatt MR, Kalani Z, Chang JJ, Okamoto M, Stegmaier K, Golub TR, Boehm JS, Vazquez F, Root DE, Hahn WC, Tsherniak A. 2017. Cell. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.",10.1038/ng.3984,https://doi.org/10.1038/ng.3984,Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells,Meyers
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DHX16,[1],"Gorbalenya AE, Koonin EV. 1993. Nucleic Acids Research. Helicases: amino acid sequence comparisons and structure-function relationships.",10.1016/s0959-440x(05)80116-2,https://doi.org/10.1016/s0959-440x(05)80116-2,Helicases: amino acid sequence comparisons and structure-function relationships,Gorbalenya
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DHX16,[2],Fuller-Pace FV. 2013. Nature Reviews Cancer. DEAD box RNA helicase functions in cancer.,10.4161/rna.23312,https://doi.org/10.4161/rna.23312,DEAD box RNA helicase functions in cancer,Fuller-Pace
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DHX16,[3],"Hart T, Moffat J. 2016. Nature Reviews Genetics. BAGEL: a computational framework for identifying essential genes from pooled library screens.",10.1186/s12859-016-1015-8,https://doi.org/10.1186/s12859-016-1015-8,BAGEL: a computational framework for identifying essential genes from pooled library screens,Hart
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--DHX16,[4],"Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. 2015. Science. Gene essentiality and synthetic lethality in haploid human cells.",10.1126/science.aac7557,https://doi.org/10.1126/science.aac7557,Gene essentiality and synthetic lethality in haploid human cells,Blomen
0,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMA7,[1],"Tomko RJ Jr, Hochstrasser M. 2013. Molecular Biology and Evolution. Molecular architecture and assembly of the eukaryotic proteasome.",10.1146/annurev-biochem-060410-150257,https://doi.org/10.1146/annurev-biochem-060410-150257,Molecular Architecture and Assembly of the Eukaryotic Proteasome,Tomko
1,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMA7,[2],"Ciechanover A, Kwon YT. 2015. Nature Reviews Molecular Cell Biology. Protein quality control by molecular chaperones in neurodegeneration.",10.3389/fnins.2017.00185,https://doi.org/10.3389/fnins.2017.00185,Protein Quality Control by Molecular Chaperones in Neurodegeneration,Ciechanover
2,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMA7,[3],Adams J. 2004. Nature Reviews Cancer. The proteasome: a suitable antineoplastic target.,10.1038/nrc1361,https://doi.org/10.1038/nrc1361,The proteasome: a suitable antineoplastic target,Adams
3,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMA7,[4],"Walter P, Ron D. 2011. Nature Reviews Molecular Cell Biology. The unfolded protein response: from stress pathway to homeostatic regulation.",10.1126/science.1209038,https://doi.org/10.1126/science.1209038,The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation,Walter
4,experiments/gene_essentiality_cancer/ai_messages/high_complexity--PSMA7,[5],"Tabas I, Ron D. 2011. Nature Cell Biology. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress.",10.1038/ncb0311-184,https://doi.org/10.1038/ncb0311-184,Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress,Tabas
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[3],"Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., ... & Nordlinger, B. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[4],"Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., ... & Taube, J. M. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmoa1500596,https://doi.org/10.1056/nejmoa1500596,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,Le
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[5],"Compton, C. C. (2007). Optimal pathologic staging: defining stage II disease. Clinical Cancer Research, 13(22), 6862s-6870s.",10.1158/1078-0432.ccr-07-1398,https://doi.org/10.1158/1078-0432.ccr-07-1398,Optimal Pathologic Staging: Defining Stage II Disease,Compton
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[6],"Franko, J., Shi, Q., Goldman, C. D., Pockaj, B. A., Nelson, G. D., Goldberg, R. M., ... & Alberts, S. R. (2012). Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. Journal of Clinical Oncology, 30(3), 263-267.",10.1200/jco.2011.37.1039,https://doi.org/10.1200/jco.2011.37.1039,Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841,Franko
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[7],"Chaffer, C. L., & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 331(6024), 1559-1564.",10.1126/science.1203543,https://doi.org/10.1126/science.1203543,A Perspective on Cancer Cell Metastasis,Chaffer
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_13,[8],American Cancer Society. (2021). Colorectal Cancer Stages. Retrieved from https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/staged.html,10.1007/978-3-030-58846-5_18,https://doi.org/10.1007/978-3-030-58846-5_18,Multidisciplinary Treatment of Rectal Cancer,Glimelius
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_EGFR_MGMT_low_methylated,[1],"Brennan CW, et al. 2013. Cell. The somatic genomic landscape of glioblastoma.",10.7717/peerj.13105/table-1,https://doi.org/10.7717/peerj.13105/table-1,"Table 1: Crown width-DBH (CW-D) candidate functions considered in the analysis (Fu et al., 2013; Raptis et al., 2018; Wang et al., 2021).",
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_EGFR_MGMT_low_methylated,[2],"Hegi ME, et al. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.3410/f.718384246.793495041,https://doi.org/10.3410/f.718384246.793495041,Faculty Opinions recommendation of MGMT gene silencing and benefit from temozolomide in glioblastoma.,Gilbert
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_EGFR_MGMT_low_methylated,[3],"Stupp R, et al. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp
0,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu
1,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley
2,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[3],"Van Cutsem, E., Cervantes, A., & Nordlinger, B. (2014). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25(suppl_3), iii1-iii9.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem
3,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[4],"Le, D. T., Uram, J. N., & Wang, H. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmc1510353,https://doi.org/10.1056/nejmc1510353,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,
4,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[5],"Compton, C. C. (2007). Prognostic factors in cancer. In Prognostic Factors in Cancer (pp. 43-86). Wiley-Liss.",10.3109/9780203089781-24,https://doi.org/10.3109/9780203089781-24,Molecular prognostic and predictive factors in cervical cancer,
5,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[6],"Van Cutsem, E., & Oliveira, J. (2009). Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 20(suppl_4), 61-63.",10.1093/annonc/mdp130,https://doi.org/10.1093/annonc/mdp130,"Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up",Van Cutsem
6,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[7],"Sargent, D. J., Goldberg, R. M., & Jacobson, S. D. (2001). A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New England Journal of Medicine, 345(15), 1091-1097.",10.1056/nejmoa010957,https://doi.org/10.1056/nejmoa010957,A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients,Sargent
7,experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_12,[8],"Franko, J., Shi, Q., & Meyers, J. P. (2012). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17(12), 1709-1719.",10.1016/s1470-2045(16)30500-9,https://doi.org/10.1016/s1470-2045(16)30500-9,Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database,Franko
